<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Transl Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Transl Psychiatry</journal-id>
<journal-title-group>
<journal-title>Translational Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">2158-3188</issn>
<publisher>
<publisher-name>Nature Publishing Group</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27351598</article-id>
<article-id pub-id-type="pmc">4931610</article-id>
<article-id pub-id-type="pii">tp201677</article-id>
<article-id pub-id-type="doi">10.1038/tp.2016.77</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders</article-title>
<alt-title alt-title-type="running">Brain inflammation and autism</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Theoharides</surname>
<given-names>T C</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
<xref ref-type="aff" rid="aff3">3</xref>
<xref ref-type="aff" rid="aff4">4</xref>
<xref ref-type="corresp" rid="caf1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsilioni</surname>
<given-names>I</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Patel</surname>
<given-names>A B</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Doyle</surname>
<given-names>R</given-names>
</name>
<xref ref-type="aff" rid="aff5">5</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff2"><label>2</label><institution>Sackler School of Graduate Biomedical Sciences, Program in Cell, Molecular and Developmental Biology, Tufts University</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center</institution>, Boston, MA, <country>USA</country></aff>
<aff id="aff5"><label>5</label><institution>Department of Child Psychiatry, Harvard Medical School, Massachusetts General Hospital and McLean Hospital</institution>, Boston, MA, <country>USA</country></aff>
</contrib-group>
<author-notes>
<corresp id="caf1"><label>*</label><institution>Molecular Immunopharmacology and Drug Discovery Laboratory, Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine</institution>, 136 Harrison Avenue, Suite J304, Boston, MA 02111, <country>USA</country>. E-mail: <email>theoharis.theoharides@tufts.edu</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>06</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>6</month>
<year>2016</year>
</pub-date>
<volume>6</volume>
<issue>6</issue>
<fpage>e844</fpage>
<lpage></lpage>
<history>
<date date-type="received">
<day>13</day>
<month>01</month>
<year>2016</year>
</date>
<date date-type="rev-recd">
<day>23</day>
<month>02</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>03</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2016 Macmillan Publishers Limited</copyright-statement>
<copyright-year>2016</copyright-year>
<copyright-holder>Macmillan Publishers Limited</copyright-holder>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--author-paid-->
<license-p>This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link></license-p>
</license>
</permissions>
<abstract>
<p>Autism spectrum disorders (ASDs) affect as many as 1 in 45 children and are characterized by deficits in sociability and communication, as well as stereotypic movements. Many children also show severe anxiety. The lack of distinct pathogenesis and reliable biomarkers hampers the development of effective treatments. As a result, most children with ASD are prescribed psychopharmacologic agents that do not address the core symptoms of ASD. Autoantibodies against brain epitopes in mothers of children with ASD and many such children strongly correlate with allergic symptoms and indicate an aberrant immune response, as well as disruption of the blood–brain barrier (BBB). Recent epidemiological studies have shown a strong statistical correlation between risk for ASD and either maternal or infantile atopic diseases, such as asthma, eczema, food allergies and food intolerance, all of which involve activation of mast cells (MCs). These unique tissue immune cells are located perivascularly in all tissues, including the thalamus and hypothalamus, which regulate emotions. MC-derived inflammatory and vasoactive mediators increase BBB permeability. Expression of the inflammatory molecules interleukin (IL-1β), IL-6, 1 L-17 and tumor necrosis factor (TNF) is increased in the brain, cerebrospinal fluid and serum of some patients with ASD, while NF-kB is activated in brain samples and stimulated peripheral blood immune cells of other patients; however, these molecules are not specific. Instead the peptide neurotensin is uniquely elevated in the serum of children with ASD, as is corticotropin-releasing hormone, secreted from the hypothalamus under stress. Both peptides trigger MC to release IL-6 and TNF, which in turn, stimulate microglia proliferation and activation, leading to disruption of neuronal connectivity. MC-derived IL-6 and TGFβ induce maturation of Th17 cells and MCs also secrete IL-17, which is increased in ASD. Serum IL-6 and TNF may define an ASD subgroup that benefits most from treatment with the natural flavonoid luteolin. Atopic diseases may create a phenotype susceptible to ASD and formulations targeting focal inflammation of the brain could have great promise in the treatment of ASD.</p>
</abstract>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Autism spectrum disorders (ASDs) are pervasive neurodevelopmental disorders characterized by deficits in communication and social interactions, as well as the presence of stereotypic behaviors.<sup><xref ref-type="bibr" rid="bib1">1</xref>, <xref ref-type="bibr" rid="bib2">2</xref>, <xref ref-type="bibr" rid="bib3">3</xref></sup> Numerous gene mutations have been identified in patients with ASD, but no direct link has so far been uncovered except for a small percentage of cases associated with Tuberous Sclerosis, Fragile X syndrome, Rett syndrome and <italic>PTEN</italic> deficiency.<sup><xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref></sup> As a result, even though there are a number of genetically-engineered mice with phenotypes resembling autism,<sup><xref ref-type="bibr" rid="bib6">6</xref></sup> they do not adequately reflect ASD and there is an urgent need for appropriate animal ‘models' of ASD.<sup><xref ref-type="bibr" rid="bib7">7</xref></sup> In fact, mouse ‘models' are increasingly considered unreliable with respect to inflammatory human diseases.<sup><xref ref-type="bibr" rid="bib8">8</xref></sup> We recently reported that a small number of bull terriers develop symptoms consistent with autism and have increased serum neurotensin (NT) and corticotropin-releasing hormone (CRH), also found to be elevated in children with ASD.<sup><xref ref-type="bibr" rid="bib9">9</xref></sup></p>
<p>ASD may affect as many as 1 in 45 children in the USA,<sup><xref ref-type="bibr" rid="bib10">10</xref></sup> but the global prevalence is still under-recognized.<sup><xref ref-type="bibr" rid="bib11">11</xref></sup> The lack of reliable biomarkers<sup><xref ref-type="bibr" rid="bib12">12</xref></sup> and specific pathogenesis,<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> as well as the existence of subgroups or comorbidities<sup><xref ref-type="bibr" rid="bib14">14</xref></sup> (<xref ref-type="table" rid="tbl1">Table 1</xref>), makes the development of specific treatments and conducting clinical studies difficult.<sup><xref ref-type="bibr" rid="bib13">13</xref></sup> As a result, child and adolescent outpatient mental health services in the USA have increased considerably.<sup><xref ref-type="bibr" rid="bib15">15</xref></sup> Moreover, the annual economic burden for ASD was recently estimated at $268 billion for 2015 and is projected to reach $416 billion in 2025.<sup><xref ref-type="bibr" rid="bib16">16</xref></sup></p>
<p>A number of perinatal allergic, genetic, environmental, immune and infectious factors may increase the risk of or contribute to the pathogenesis of ASD<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib19">19</xref></sup> (<xref ref-type="table" rid="tbl2">Table 2</xref>). These could act through activation of a unique tissue immune cell, the mast cell (MC).<sup><xref ref-type="bibr" rid="bib20">20</xref>, <xref ref-type="bibr" rid="bib21">21</xref></sup> MCs derive from bone marrow progenitors and mature in tissues depending on microenvironmental conditions.<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> In addition to histamine, stimulated MCs secrete other vasoactive and pro-inflammatory mediators such as the preformed kinins and proteases, as well as the <italic>de novo</italic> synthesized leukotrienes, prostaglandins, chemokines (CCXL8, CCL2), cytokines (interleukin (IL)-4, IL-6, IL-1, tumor necrosis factor (TNF)) and vascular endothelial growth factor (VEGF).<sup><xref ref-type="bibr" rid="bib20">20</xref></sup></p>
<p>MCs are not only considered critical for the development of allergic reactions,<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> but also for immunity<sup><xref ref-type="bibr" rid="bib22">22</xref></sup> and inflammation.<sup><xref ref-type="bibr" rid="bib23">23</xref></sup> In fact, many studies have reported that allergic diseases in preschoolers are strongly associated with psychological and behavioral problems.<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> We had proposed that MC-derived mediators could disrupt the blood–brain barrier (BBB) and cause 'allergy of the brain'<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> or ‘focal encephalitis',<sup><xref ref-type="bibr" rid="bib26">26</xref></sup> thus contributing to the pathogenesis of ASD.<sup><xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib27">27</xref></sup> A number of recent reviews have now confirmed and expanded on these findings.<sup><xref ref-type="bibr" rid="bib28">28</xref>, <xref ref-type="bibr" rid="bib29">29</xref></sup></p>
</sec>
<sec>
<title>Maternal health, prematurity and low birth weight are linked to increased risk of ASD</title>
<p>Obesity during gestation has been strongly associated with prematurity and low birth weight.<sup><xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref></sup> Obesity is considered as an inflammatory state<sup><xref ref-type="bibr" rid="bib32">32</xref></sup> and has been associated with activation of MCs.<sup><xref ref-type="bibr" rid="bib33">33</xref>, <xref ref-type="bibr" rid="bib34">34</xref></sup> Moreover, MCs secrete leptin<sup><xref ref-type="bibr" rid="bib35">35</xref></sup> and its deficiency switches MC to an anti-inflammatory phenotype.<sup><xref ref-type="bibr" rid="bib36">36</xref></sup> Leptin is increased both in obesity<sup><xref ref-type="bibr" rid="bib37">37</xref></sup> and ASD.<sup><xref ref-type="bibr" rid="bib38">38</xref></sup> Premature births account for about 15% of all births in the USA and premature infants (32–36 weeks) make up most of the increased rate of prematurity.<sup><xref ref-type="bibr" rid="bib39">39</xref></sup> Such infants are at risk for neurologic injury<sup><xref ref-type="bibr" rid="bib40">40</xref>, <xref ref-type="bibr" rid="bib41">41</xref></sup> associated with decreased attention, increased anxiety, as well as social interaction and learning difficulties.<sup><xref ref-type="bibr" rid="bib42">42</xref></sup></p>
<p>A retrospective study reported that children &lt;33 weeks gestation were associated with a twofold higher risk of ASD.<sup><xref ref-type="bibr" rid="bib43">43</xref></sup> One prospective study found that 26% very low birth weight (&lt;1500 g) infants ((<italic>n</italic>=91), mean age of 22 months) developed ASD.<sup><xref ref-type="bibr" rid="bib44">44</xref></sup> There was a higher risk of infantile autism among children with low birth weight especially in mothers &gt;35 years, foreign born and those who had psychoactive medicines during pregnancy.<sup><xref ref-type="bibr" rid="bib45">45</xref></sup> Another case-control population-based cohort study among Swedish children <italic>(n</italic>=408, born 1974–1993), reported that the risk of ASD was associated with being small for gestational age, daily maternal smoking in early pregnancy, maternal birth outside Europe and North America, a 5-min APGAR score &lt;7 and congenital malformations.<sup><xref ref-type="bibr" rid="bib46">46</xref></sup></p>
<p>Perinatal stress has been linked to increased risk of ASD.<sup><xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib47">47</xref></sup> Such stress may be linked to sexual abuse that has been associated with higher risk of ASD.<sup><xref ref-type="bibr" rid="bib48">48</xref>, <xref ref-type="bibr" rid="bib49">49</xref></sup> ASD patients are prone to stress<sup><xref ref-type="bibr" rid="bib50">50</xref></sup> and a meta-analysis showed a strong correlation between the presence of anxiety disorders and ASD.<sup><xref ref-type="bibr" rid="bib51">51</xref></sup> In fact, anxiety was significantly correlated with repetitive behaviors in children with ASD.<sup><xref ref-type="bibr" rid="bib52">52</xref></sup> We reported that the peptides NT<sup><xref ref-type="bibr" rid="bib53">53</xref></sup> and CRH<sup><xref ref-type="bibr" rid="bib9">9</xref></sup> secreted under stress were increased in the serum of young children with ASD, as compared with normal controls.<sup><xref ref-type="bibr" rid="bib53">53</xref></sup> The highest expression of NT receptors in the human brain is in the amygdala,<sup><xref ref-type="bibr" rid="bib54">54</xref></sup> hypothalamus and area of Broca,<sup><xref ref-type="bibr" rid="bib55">55</xref></sup> which regulate emotions and language, respectively. Stress can activate MCs through CRH leading to increased BBB permeability.<sup><xref ref-type="bibr" rid="bib56">56</xref></sup> Moreover, CRH has synergistic actions with NT, stimulating secretion of VEGF and increasing vascular permeability.<sup><xref ref-type="bibr" rid="bib53">53</xref></sup> Human MCs express CRHR-1,<sup><xref ref-type="bibr" rid="bib57">57</xref></sup> activation of which by CRH leads to VEGF secretion and BBB disruption<sup><xref ref-type="bibr" rid="bib58">58</xref></sup> and NT stimulates secretion of VEGF.<sup><xref ref-type="bibr" rid="bib57">57</xref></sup></p>
<p>A recent review concluded that stress during gestation increases the risk for developing atopic diseases in infants.<sup><xref ref-type="bibr" rid="bib59">59</xref></sup> Moreover, stress has been associated with precipitating or worsening asthma<sup><xref ref-type="bibr" rid="bib60">60</xref></sup> and multiple sclerosis.<sup><xref ref-type="bibr" rid="bib61">61</xref></sup></p>
</sec>
<sec>
<title>Atopic diseases are strongly correlated with increased risk of ASD</title>
<p>Recent studies have shown strong associations between allergies, asthma, autoimmune diseases and psoriasis in the mother with increased risk for ASD in their children.<sup><xref ref-type="bibr" rid="bib62">62</xref>, <xref ref-type="bibr" rid="bib63">63</xref>, <xref ref-type="bibr" rid="bib64">64</xref></sup> Moreover, mothers with mastocytosis or MC activation syndrome were much more likely to have children who developed ASD.<sup><xref ref-type="bibr" rid="bib65">65</xref></sup></p>
<p>Allergies<sup><xref ref-type="bibr" rid="bib66">66</xref></sup> and auto-immune diseases<sup><xref ref-type="bibr" rid="bib67">67</xref>, <xref ref-type="bibr" rid="bib68">68</xref></sup> have been increasing significantly. Early reports indicated more frequent allergies in ASD children,<sup><xref ref-type="bibr" rid="bib69">69</xref>, <xref ref-type="bibr" rid="bib70">70</xref></sup> with food allergies being the most prevalent complaint, often in the absence of elevated serum IgE or positive skin tests.<sup><xref ref-type="bibr" rid="bib71">71</xref>, <xref ref-type="bibr" rid="bib72">72</xref>, <xref ref-type="bibr" rid="bib73">73</xref></sup> A large epidemiological study of noninstitutionalized children (<italic>n</italic>=92 642; 0–17 years old) showed that eczema was strongly associated with ASD and attention deficit hyperactivity disorder.<sup><xref ref-type="bibr" rid="bib74">74</xref></sup> Another study of atopic subjects (<italic>n</italic>=14 812; 3 years old) and non-atopic subjects (<italic>n</italic>=6944) also showed a strong association between atopy and risk of both ASD and attention deficit hyperactivity disorder.<sup><xref ref-type="bibr" rid="bib75">75</xref></sup> A case control study of children and young patients with ASD (<italic>n</italic>=5565) and controls (<italic>n</italic>=27 825) matched to birth year (1980–2003) and sex reported that allergies, asthma and autoimmune disorders were diagnosed more frequently, with psoriasis occurring more than twice as often, in ASD patients than controls.<sup><xref ref-type="bibr" rid="bib76">76</xref></sup> An experimental study actually reported neurochemical changes and autistic-like behavior in a mouse model of food allergy.<sup><xref ref-type="bibr" rid="bib77">77</xref></sup></p>
<p>MCs can be activated by fungi,<sup><xref ref-type="bibr" rid="bib78">78</xref></sup> such as <italic>Aspergillus fumigatus</italic> which triggers IgE-independent MC degranulation<sup><xref ref-type="bibr" rid="bib79">79</xref></sup> and fungal zymosan induces leukotriene production from human MCs.<sup><xref ref-type="bibr" rid="bib80">80</xref></sup> Moreover, MCs can be stimulated by aluminum and mercury.<sup><xref ref-type="bibr" rid="bib81">81</xref>, <xref ref-type="bibr" rid="bib82">82</xref></sup></p>
</sec>
<sec>
<title>Perinatal epigenetic environmental triggers contribute to inflammation of the brain and increase risk of ASD</title>
<p>Environmental triggers have been increasingly invoked in ASD.<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib83">83</xref>, <xref ref-type="bibr" rid="bib84">84</xref>, <xref ref-type="bibr" rid="bib85">85</xref>, <xref ref-type="bibr" rid="bib86">86</xref></sup> Chemical intolerant mothers were three times more likely to have a child who developed ASD and these children were more prone to allergies and sensitivities, including odors.<sup><xref ref-type="bibr" rid="bib87">87</xref></sup> Exposure to mold has been linked to decreased cognitive function in children<sup><xref ref-type="bibr" rid="bib88">88</xref></sup> and volatile mycotoxins have been reported to induce neuropsychiatric symptoms.<sup><xref ref-type="bibr" rid="bib89">89</xref></sup></p>
<p>Both mercury<sup><xref ref-type="bibr" rid="bib90">90</xref></sup> and aluminum<sup><xref ref-type="bibr" rid="bib91">91</xref>, <xref ref-type="bibr" rid="bib92">92</xref></sup> have been associated with symptom severity in children with ASD and both can stimulate MCs.<sup><xref ref-type="bibr" rid="bib81">81</xref></sup> Aluminum has replaced mercury as an adjuvant in vaccines, but aluminum can cause DNA damage<sup><xref ref-type="bibr" rid="bib93">93</xref></sup> and induce microglia TNF release.<sup><xref ref-type="bibr" rid="bib94">94</xref></sup> The adjuvant activity of aluminum was shown to be mediated through DNA released from dying cells, possibly through production of IgE and IgG<sub>1</sub>, known MC triggers.<sup><xref ref-type="bibr" rid="bib95">95</xref></sup> Such ‘damage-associated molecular patterns' can act as ‘alarmins'<sup><xref ref-type="bibr" rid="bib96">96</xref></sup> and cause inflammatory responses through toll-like receptors, which participate in immunity against bacterial infections<sup><xref ref-type="bibr" rid="bib97">97</xref>, <xref ref-type="bibr" rid="bib98">98</xref></sup> and are also expressed on MCs.<sup><xref ref-type="bibr" rid="bib99">99</xref></sup></p>
<p>Stimulated human MCs can secrete mitochondrial DNA (mtDNA) and ATP extracellularly without cell death.<sup><xref ref-type="bibr" rid="bib100">100</xref></sup> These mitochondrial components augmented allergic responses<sup><xref ref-type="bibr" rid="bib101">101</xref></sup> and could act as ‘innate pathogens' triggering inflammation and potentially contributing to ASD.<sup><xref ref-type="bibr" rid="bib102">102</xref></sup> mtDNA is also directly neurotoxic in rat brain slices.<sup><xref ref-type="bibr" rid="bib103">103</xref></sup> We reported that serum mtDNA is elevated in young autistic children as compared with controls.<sup><xref ref-type="bibr" rid="bib104">104</xref></sup> The pathological importance of extracellular mtDNA could be even more relevant in the subgroup of ASD patients with mitochondrial dysfunction.<sup><xref ref-type="bibr" rid="bib105">105</xref></sup></p>
<p>MCs are therefore considered important for inflammation.<sup><xref ref-type="bibr" rid="bib23">23</xref></sup><sup>,</sup><sup><xref ref-type="bibr" rid="bib106">106</xref></sup></p>
</sec>
<sec>
<title>Evidence for inflammation of the brain in ASD patients</title>
<p>Increasing evidence indicates that perinatal brain inflammation,<sup><xref ref-type="bibr" rid="bib18">18</xref>, <xref ref-type="bibr" rid="bib107">107</xref></sup> may contribute to the pathogenesis of neuropsychiatric disorders,<sup><xref ref-type="bibr" rid="bib108">108</xref>, <xref ref-type="bibr" rid="bib109">109</xref></sup> including ASD.<sup><xref ref-type="bibr" rid="bib26">26</xref>, <xref ref-type="bibr" rid="bib110">110</xref></sup> It was previously reported that ASD pathogenesis involves some immune<sup><xref ref-type="bibr" rid="bib17">17</xref>, <xref ref-type="bibr" rid="bib111">111</xref>, <xref ref-type="bibr" rid="bib112">112</xref>, <xref ref-type="bibr" rid="bib113">113</xref></sup> and autoimmune<sup><xref ref-type="bibr" rid="bib102">102</xref>, <xref ref-type="bibr" rid="bib114">114</xref></sup> components. Circulating auto-antibodies directed against fetal brain proteins have been reported in mothers of children with ASD<sup><xref ref-type="bibr" rid="bib115">115</xref>, <xref ref-type="bibr" rid="bib116">116</xref></sup> and in about 37% of ASD patients,<sup><xref ref-type="bibr" rid="bib117">117</xref></sup> implying BBB disruption which is regulated through MCs.<sup><xref ref-type="bibr" rid="bib56">56</xref>, <xref ref-type="bibr" rid="bib118">118</xref></sup> The presence of auto-brain antibodies significantly correlated with allergic symptoms.<sup><xref ref-type="bibr" rid="bib119">119</xref></sup></p>
<p>A number of inflammatory molecules have been shown to be increased in the brain and cerebrospinal fluid of many ASD patients including IL-1β, IL-6, TNF, MCP-1 and CCL8 (IL-8) <sup><xref ref-type="bibr" rid="bib120">120</xref>, <xref ref-type="bibr" rid="bib121">121</xref>, <xref ref-type="bibr" rid="bib122">122</xref></sup> (<xref ref-type="table" rid="tbl3">Table 3</xref>). Plasma levels of IL-1β, IL-6 and IL-8 were increased in children with ASD and correlated with regression, as well as impaired communication and aberrant behavior.<sup><xref ref-type="bibr" rid="bib123">123</xref></sup></p>
<p>Analysis of cytokines in neonatal blood showed that IL-1β and IL-4 linked to severe ASD.<sup><xref ref-type="bibr" rid="bib124">124</xref></sup> In a previous study by some of the same authors, these cytokines were not detected apparently due to the sensitivity of the assay used.<sup><xref ref-type="bibr" rid="bib125">125</xref></sup> Increased maternal serum concentrations of IFN-γ, IL-4 and IL-5 during midgestation were significantly associated with a 50% increased risk of ASD.<sup><xref ref-type="bibr" rid="bib126">126</xref></sup></p>
<p>MC-derived TNF can promote Th17-dependent neutrophil recruitment.<sup><xref ref-type="bibr" rid="bib127">127</xref></sup> Moreover, MC-derived IL-6 and TGFβ promote the devlopment of Th17 cells.<sup><xref ref-type="bibr" rid="bib128">128</xref></sup> In fact, MCs can also secrete IL-17<sup><xref ref-type="bibr" rid="bib129">129</xref></sup> and IL-17 was reported to be increased in the serum of children with ASD.<sup><xref ref-type="bibr" rid="bib130">130</xref></sup> There was an increased IL-17 production from peripheral blood immune cells following mitogen stimulation, and IL-17 was further increased in ASD children with comorbid asthma.<sup><xref ref-type="bibr" rid="bib131">131</xref></sup> A recent paper reported that selective elimination of Th17 cells in the maternal immune activation (MIA) mouse model prevented the development of autism-like behaivor in the offspring.<sup><xref ref-type="bibr" rid="bib132">132</xref></sup></p>
<p>The MIA model was also associated with increased serum IL-6,<sup><xref ref-type="bibr" rid="bib133">133</xref></sup> and the autism-like behavior was absent in IL-6<sup>−/−</sup> mice.<sup><xref ref-type="bibr" rid="bib134">134</xref></sup> We had reported that acute stress significantly increases serum IL-6 in mice that was entirely dependent on MCs, as it was absent in MC-deficient W/W<sup>v</sup> mice.<sup><xref ref-type="bibr" rid="bib135">135</xref></sup> In fact, human MC can undergo selective release of IL-6 without degranulation.<sup><xref ref-type="bibr" rid="bib136">136</xref></sup> Mastocytosis patients have increased serum IL-6 that correlates with disease activity<sup><xref ref-type="bibr" rid="bib137">137</xref>, <xref ref-type="bibr" rid="bib138">138</xref>, <xref ref-type="bibr" rid="bib139">139</xref></sup> and children with mastocytosis had a 10-fold higher risk of developing ASD than the general population,<sup><xref ref-type="bibr" rid="bib65">65</xref></sup> implying activation of MCs.<sup><xref ref-type="bibr" rid="bib27">27</xref></sup></p>
<p>MCP-1 in amniotic fluid was strongly correlated with increased risk for infantile autism<sup><xref ref-type="bibr" rid="bib140">140</xref></sup> and MCP-1 was also elevated in archived neonatal blood specimens.<sup><xref ref-type="bibr" rid="bib125">125</xref></sup> MCP-1 is chemotactic for MCs,<sup><xref ref-type="bibr" rid="bib23">23</xref></sup> which can secrete both pre-formed and newly synthesized TNF.<sup><xref ref-type="bibr" rid="bib141">141</xref></sup> TGF-beta has been reported to be low in the brains of children with ASD,<sup><xref ref-type="bibr" rid="bib142">142</xref></sup> a finding that may contribute to the inflammatory state since TGF-beta inhibits MCs.<sup><xref ref-type="bibr" rid="bib143">143</xref>, <xref ref-type="bibr" rid="bib144">144</xref></sup></p>
<p>Peripheral blood mononuclear cells from patients with ASD (<italic>n</italic>=23) produced twice as much TNF as those from controls (<italic>n</italic>=13) when stimulated even by gliadin, cow's milk protein or soy.<sup><xref ref-type="bibr" rid="bib145">145</xref></sup> NF-κB DNA-binding activity, involved in TNF production, was twice as much in peripheral blood from patients with ASD (<italic>n</italic>=67) than controls (<italic>n</italic>=29).<sup><xref ref-type="bibr" rid="bib146">146</xref></sup> Neurons, astrocytes and microglia from patients with ASD had higher expression of NF-κB p65 as compared with matched controls.<sup><xref ref-type="bibr" rid="bib147">147</xref></sup> Moreover, signaling through NF-κB was prominent in interacting gene networks constructed from brains of ASD patients.<sup><xref ref-type="bibr" rid="bib148">148</xref></sup></p>
<p>MCs have recently been considered important in neuroinflammation.<sup><xref ref-type="bibr" rid="bib149">149</xref></sup></p>
</sec>
<sec>
<title>MC–microglia interactions in the pathogenesis of ASD</title>
<p>Microglia, the innate brain immune cells,<sup><xref ref-type="bibr" rid="bib150">150</xref></sup> are important during healthy brain development because they may ‘prune' neural circuits.<sup><xref ref-type="bibr" rid="bib151">151</xref>, <xref ref-type="bibr" rid="bib152">152</xref></sup> However, abnormal microglia activation and proliferation could lead to focal inflammation and ‘choking' of normal synaptic traffic as has been reported in brains of patients with ASD.<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib153">153</xref>, <xref ref-type="bibr" rid="bib154">154</xref>, <xref ref-type="bibr" rid="bib155">155</xref></sup> A recent study of the transcriptomes from 104 human brain cortical tissue samples from patients with ASD identified gene clusters associated with increased microglia activation (M2) and decreased neuronal activity.<sup><xref ref-type="bibr" rid="bib156">156</xref></sup> As a result, microglia are now considered an important component of the pathogenesis of ASD.<sup><xref ref-type="bibr" rid="bib157">157</xref>, <xref ref-type="bibr" rid="bib158">158</xref></sup></p>
<p>Human microglia express functional CRHR1<sup><xref ref-type="bibr" rid="bib159">159</xref></sup> and NTR3 (sortilin), activation of which leads to microglia proliferation.<sup><xref ref-type="bibr" rid="bib160">160</xref></sup> NTR3 has been implicated in neuronal viability and function<sup><xref ref-type="bibr" rid="bib161">161</xref></sup> and increased soluble sortilin has been associated with depression, corresponding to elevated levels of BDNF and VEGF.<sup><xref ref-type="bibr" rid="bib162">162</xref></sup> NT can be neurotoxic by facilitating <italic>N</italic>-Methyl-<sc>d</sc>-aspartate-induced excitation of cortical neurons.<sup><xref ref-type="bibr" rid="bib163">163</xref></sup> We recently reported that NT stimulates activation and proliferation of human microglia.<sup><xref ref-type="bibr" rid="bib164">164</xref></sup> We believe this is the first time that a neuropeptide elevated in ASD is shown to stimulate human microglia that are now believed to play a major role in the pathogenesis of ASD.<sup><xref ref-type="bibr" rid="bib39">39</xref>, <xref ref-type="bibr" rid="bib153">153</xref>, <xref ref-type="bibr" rid="bib154">154</xref></sup> NT can therefore stimulate both microglia and MCs (<xref ref-type="fig" rid="fig1">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bib53">53</xref></sup></p>
<p>Signaling through the mammalian target of rapamycin (mTOR) has been implicated in ASD<sup><xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib165">165</xref></sup> and mutations of the mTOR upstream regulatory molecule phosphatase and tensin homolog (PTEN)<sup><xref ref-type="bibr" rid="bib166">166</xref></sup> and tuberous sclerosis complex 1 and 2 (TSC 1/2)<sup><xref ref-type="bibr" rid="bib167">167</xref></sup> have been associated with higher risk of ASD.<sup><xref ref-type="bibr" rid="bib167">167</xref></sup> We recently showed that activation of NTR3 induced activation of human cultured microglia, which was regulated by mTOR.<sup><xref ref-type="bibr" rid="bib164">164</xref></sup> PTEN and mTOR are also involved in MC activation and proliferation.<sup><xref ref-type="bibr" rid="bib168">168</xref></sup></p>
<p>MC-derived histamine<sup><xref ref-type="bibr" rid="bib169">169</xref></sup> and tryptase<sup><xref ref-type="bibr" rid="bib170">170</xref></sup> can stimulate microglia, findings that have led to the proposal that MC-microglia interactions are important in neuroinflammation.<sup><xref ref-type="bibr" rid="bib171">171</xref>, <xref ref-type="bibr" rid="bib172">172</xref></sup> Stimulation of brain MC in mice was recently shown to induce microglia activation and brain inflammation, inhibited by a MC stabilizer.<sup><xref ref-type="bibr" rid="bib172">172</xref></sup></p>
<p>It is, therefore, important to address neuroinflammation as a possible treatment option for ASD.</p>
</sec>
<sec>
<title>Treatment approaches</title>
<p>Most children with ASD are often prescribed psychotropic medications,<sup><xref ref-type="bibr" rid="bib173">173</xref></sup> primarily risperidone and aripiprazole to reduce disruptive and aggressive behaviors, but these drugs have no effect on the core symptoms of ASD.<sup><xref ref-type="bibr" rid="bib174">174</xref>, <xref ref-type="bibr" rid="bib175">175</xref></sup> In fact, recent studies have questioned the benefit of psychotropic agents and have highlighted frequent adverse effects such as weight gain, sedation, tremor, movement disorders and drooling.<sup><xref ref-type="bibr" rid="bib176">176</xref></sup> As a result, there is increased polypharmacy<sup><xref ref-type="bibr" rid="bib174">174</xref>, <xref ref-type="bibr" rid="bib177">177</xref></sup> and risk of unwanted drug interactions.<sup><xref ref-type="bibr" rid="bib178">178</xref></sup></p>
<p>There should be concerted efforts toward developing effective treatments for ASD, such as the European Autism Interventions-A MultiCentre Study for Developing New Medications (EU-AIMS) Initiative.<sup><xref ref-type="bibr" rid="bib179">179</xref></sup></p>
<p>Immunomodulatory treatments have been considered for ASD,<sup><xref ref-type="bibr" rid="bib180">180</xref></sup> but few studies have been published. Some reports have hypothesized that the increase in ASD is linked to the increased use of the antipyretic acetaminophen.<sup><xref ref-type="bibr" rid="bib181">181</xref></sup> On the contrary, some families report that high fever reduces symptoms temporarily.<sup><xref ref-type="bibr" rid="bib182">182</xref></sup></p>
<sec>
<title>Immune Ig</title>
<p>Intravenous (i.v.) immunoglobulin treatment (commonly known as immune Ig) has been used in ASD.<sup><xref ref-type="bibr" rid="bib183">183</xref>, <xref ref-type="bibr" rid="bib184">184</xref></sup> In one study, i.v. Ig (200 to 400 mg kg<sup>−1</sup>, every 6 weeks × 2) was administered to children with ASD (<italic>n</italic>=10) with one child showing significant and four children showing mild improvement.<sup><xref ref-type="bibr" rid="bib185">185</xref></sup> Three pilot open clinical trials showed some benefit.<sup><xref ref-type="bibr" rid="bib186">186</xref>, <xref ref-type="bibr" rid="bib187">187</xref>, <xref ref-type="bibr" rid="bib188">188</xref></sup></p>
<p>The usefulness of this approach may be even more apparent in children with ASD whose plasma levels of IgG and IgM were reported to be low in spite of apparently normal numbers of B cells.<sup><xref ref-type="bibr" rid="bib189">189</xref></sup></p>
</sec>
<sec>
<title>Macrophage activating factor (GcMAF)</title>
<p>This molecule, an endogenous glycosylated vitamin D-binding protein, which promotes macrophage cell activation, downregulated the over-activation of blood monocyte-derived macrophages observed in autistic children (<italic>n</italic>=22, 3–11 years old) compared with age-matched healthy developing controls (<italic>n</italic>=20).<sup><xref ref-type="bibr" rid="bib190">190</xref></sup></p>
</sec>
<sec>
<title>Antioxidant compounds</title>
<p>A recent double-blind, placebo-controlled, study using the broccoli-derived anti-oxidant sulforaphane in adult patients with ASD (<italic>n</italic>=40, 13–27 years old, selected for their history of reduced symptoms during febrile episodes) for 18 weeks showed significant improvement (34%) in social interaction and communication using the Aberrant Behavior Checklist (ABC) scale;<sup><xref ref-type="bibr" rid="bib191">191</xref></sup> however, the apparent significance was due to the uncharacteristically low placebo effect (&lt;3.3%). Placebo effects have been reported as high as 40–60% in studies of neuropsychiatric diseases.<sup><xref ref-type="bibr" rid="bib192">192</xref></sup></p>
<p>Another antioxidant, <italic>N</italic>-acetylcysteine (NAC), has also been tested. In one randomized, placebo-controlled, trial (<italic>n</italic>=13) increasing doses of NAC (900 mg per day × 4 weeks, then 900 mg twice daily × 4 weeks and finally 900 mg three times daily × 4 weeks) found no difference on the total ABC, but significant improvement on the irritability subscale.<sup><xref ref-type="bibr" rid="bib193">193</xref></sup> In another also randomized, double-blind, placebo-controlled, study (<italic>n</italic>=40), NAC added to a stable dose of risperidone, again had no effect on total ABC, but decreased the irritability subscale.<sup><xref ref-type="bibr" rid="bib194">194</xref>, <xref ref-type="bibr" rid="bib195">195</xref></sup> NAC treatment appears to be safe and well-tolerated.<sup><xref ref-type="bibr" rid="bib195">195</xref></sup> Similar results were obtained in a more recent randomized, double-blind, placebo-controlled clinical trial of children with ASD (<italic>n</italic>=40) who were given NAC (600–900 mg per day) and risperidone titrated (between 1 and 2.0 mg per day); by week 10, the NAC group showed significantly less irritability using the ABC-C irritability subscale (<italic>P</italic>=0.02).<sup><xref ref-type="bibr" rid="bib196">196</xref></sup></p>
</sec>
<sec>
<title>Anti-inflammatory compounds</title>
<p>An open-label study investigated a formulation containing the natural flavonoids luteolin and quercetin ((100 mg each per softgel capsule in olive kernel oil to increase oral absorption) 1 capsule per 10 kg weight per day for 6 months) in children with ASD (4–10 years old, <italic>n</italic>=50) and reported significant (<italic>P</italic>&lt;0.005) improvement in attention and behavior (34% in total ABC and 8.43 months in age-equivalent scores in the VABS communications domain).<sup><xref ref-type="bibr" rid="bib197">197</xref></sup> A subgroup of children in that study improved even more (65%) and were the ones with highest serum TNF and IL-6 at the beginning of the study, the levels of which dropped below basal levels at the end of treatment.<sup><xref ref-type="bibr" rid="bib122">122</xref></sup> These results indicate that objective inflammation markers may identify a subgroup of children with ASD, who are most amenable to treatment with luteolin or quercetin. A case series using the same formulation in children with ASD and atopic diseases (<italic>n</italic>=17, 4–12 years old) reported 65% improvement in attention and communication.<sup><xref ref-type="bibr" rid="bib198">198</xref></sup> Luteolin also improved ‘brain fog', characterized by reduced attention span, memory and learning<sup><xref ref-type="bibr" rid="bib199">199</xref></sup> in adults.</p>
<p>Luteolin (5, 7, 3′, 4′-tetrahydroxyflavone) is naturally found in green plants, herbs and seeds <sup><xref ref-type="bibr" rid="bib200">200</xref></sup> and is structurally related to 7, 8-dihydroxyflavone, which was shown to have brain-derived neurotrophic factor (BDNF) activity<sup><xref ref-type="bibr" rid="bib201">201</xref></sup> (<xref ref-type="table" rid="tbl3">Table 3</xref>). Low BDNF was associated with autistic-like-behavior in mice<sup><xref ref-type="bibr" rid="bib202">202</xref></sup> and 7, 8-dihydroxyflavone reduced symptoms in a mouse model of Rett syndrome,<sup><xref ref-type="bibr" rid="bib203">203</xref></sup> which is strongly associated with ASD.<sup><xref ref-type="bibr" rid="bib204">204</xref></sup></p>
<p>Luteolin and its structurally related flavonol quercetin (5, 7, 11, 3′, 4′-pentahydroxyflavonol) inhibit histamine, IL-6, IL-8, TNF and tryptase release from human MCs.<sup><xref ref-type="bibr" rid="bib205">205</xref>, <xref ref-type="bibr" rid="bib206">206</xref></sup> We recently showed that tetramethoxyluteolin is a more potent inhibitor of human MCs than luteolin.<sup><xref ref-type="bibr" rid="bib207">207</xref></sup> Luteolin also inhibits microglial activation and proliferation,<sup><xref ref-type="bibr" rid="bib208">208</xref></sup> especially IL-6 release,<sup><xref ref-type="bibr" rid="bib209">209</xref></sup> and is neuroprotective.<sup><xref ref-type="bibr" rid="bib210">210</xref></sup> Luteolin also prevented autism-like behavior in a mouse ‘model' of autism.<sup><xref ref-type="bibr" rid="bib211">211</xref></sup> Flavonoids are generally considered safe<sup><xref ref-type="bibr" rid="bib212">212</xref>, <xref ref-type="bibr" rid="bib213">213</xref></sup> and now being increasingly discussed for the treatment of neurodegenerative disorders.<sup><xref ref-type="bibr" rid="bib214">214</xref></sup></p>
</sec>
</sec>
<sec>
<title>Conclusions</title>
<p>Substantial evidence indicates that the presence of atopic diseases increases the risk of ASD and that inflammation of the brain may be involved in the pathogenesis of ASD. Addressing allergic symptoms, as well as reducing BBB permeability and inflammation of the brain, could provide significant benefit in ASD. Luteolin analogs with better bioavailability and BDNF activity should be investigated further. Intranasal administration to penetrate the brain through the cribriform plexus could deliver anti-inflammatory molecules directly to the brain. Such formulations could further be prepared in liposomes to contain molecules that target them to microglia.</p>
</sec>
</body>
<back>
<ack>
<p>Aspects of our work discussed were funded in part by the Autism Research Institute, the National Autism Association, Safe Minds, the Nancy Lurie Marks Foundation and The Jane Botsford Johnson Foundation.</p>
</ack>
<fn-group>
<fn fn-type="conflict">
<p>TCT has been awarded US Patents No 8268365; 9050275 and 9176146 covering treatment of brain inflammation and of ASD. He has developed the luteolin-containing dietary supplements BrainGain, NeuroProtek and NeuroProtek-low phenol. The remaining authors declare no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<ref id="bib1">
<mixed-citation publication-type="journal">Lai MC, Lombardo MV, Baron-Cohen S. <article-title>Autism</article-title>. <source/>Lancet
<year>2014</year>; <volume>383</volume>: <fpage>896</fpage>–910.<pub-id pub-id-type="pmid">24074734</pub-id></mixed-citation>
</ref>
<ref id="bib2">
<mixed-citation publication-type="journal">Volkmar FR, McPartland JC. <article-title>From Kanner to DSM-5: autism as an evolving diagnostic concept</article-title>. <source/>Annu Rev Clin Psychol
<year>2014</year>; <volume>10</volume>: <fpage>193</fpage>–212.<pub-id pub-id-type="pmid">24329180</pub-id></mixed-citation>
</ref>
<ref id="bib3">
<mixed-citation publication-type="journal">Fombonne E. <article-title>Epidemiology of pervasive developmental disorders</article-title>. <source/>Pediatr Res
<year>2009</year>; <volume>65</volume>: <fpage>591</fpage>–598.<pub-id pub-id-type="pmid">19218885</pub-id></mixed-citation>
</ref>
<ref id="bib4">
<mixed-citation publication-type="journal">Geschwind DH, State MW. <article-title>Gene hunting in autism spectrum disorder: on the path to precision medicine</article-title>. <source/>Lancet Neurol
<year>2015</year>; <volume>11</volume>: <fpage>1109</fpage>–1120.</mixed-citation>
</ref>
<ref id="bib5">
<mixed-citation publication-type="journal">Willsey AJ, State MW. <article-title>Autism spectrum disorders: from genes to neurobiology</article-title>. <source/>Curr Opin Neurobiol
<year>2015</year>; <volume>30</volume>: <fpage>92</fpage>–99.<pub-id pub-id-type="pmid">25464374</pub-id></mixed-citation>
</ref>
<ref id="bib6">
<mixed-citation publication-type="journal">Kazdoba TM, Leach PT, Crawley JN. <article-title>Behavioral phenotypes of genetic mouse models of autism</article-title>. <source/>Genes Brain Behav
<year>2015</year>; <volume>15</volume>: <fpage>7</fpage>–26.<pub-id pub-id-type="pmid">26403076</pub-id></mixed-citation>
</ref>
<ref id="bib7">
<mixed-citation publication-type="journal">Ruhela RK, Prakash A, Medhi B. <article-title>An urgent need for experimental animal model of autism in drug development</article-title>. <source/>Ann Neurosci
<year>2015</year>; <volume>22</volume>: <fpage>44</fpage>–49.<pub-id pub-id-type="pmid">26124551</pub-id></mixed-citation>
</ref>
<ref id="bib8">
<mixed-citation publication-type="journal">Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W et al. <article-title>Genomic responses in mouse models poorly mimic human inflammatory diseases</article-title>. <source/>Proc Natl Acad Sci USA
<year>2013</year>; <volume>110</volume>: <fpage>3507</fpage>–3512.<pub-id pub-id-type="pmid">23401516</pub-id></mixed-citation>
</ref>
<ref id="bib9">
<mixed-citation publication-type="journal">Tsilioni I, Dodman N, Petra AI, Taliou A, Francis K, Moon-Fanelli AA et al. <article-title>Elevated serum neurotensin and CRH levels in children with autistic spectrum disorders and tail-chasing bull terriers with a phenotype similar to autism</article-title>. <source/>Transl Psychiatry
<year>2014</year>; <volume>4</volume>: <fpage>e466</fpage>.<pub-id pub-id-type="pmid">25313509</pub-id></mixed-citation>
</ref>
<ref id="bib10">
<mixed-citation publication-type="journal">Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal InvestigatorsCenters for Disease Control and Prevention (CDC). <article-title>Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010</article-title>. <source/>MMWR Surveill Summ
<year>2014</year>; <volume>63</volume>: <fpage>1</fpage>–21.</mixed-citation>
</ref>
<ref id="bib11">
<mixed-citation publication-type="journal">Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C et al. <article-title>Global prevalence of autism and other pervasive developmental disorders</article-title>. <source/>Autism Res
<year>2012</year>; <volume>5</volume>: <fpage>160</fpage>–179.<pub-id pub-id-type="pmid">22495912</pub-id></mixed-citation>
</ref>
<ref id="bib12">
<mixed-citation publication-type="journal">Ruggeri B, Sarkans U, Schumann G, Persico AM. <article-title>Biomarkers in autism spectrum disorder: the old and the new</article-title>. <source/>Psychopharmacology (Berl)
<year>2014</year>; <volume>231</volume>: <fpage>1201</fpage>–1216.<pub-id pub-id-type="pmid">24096533</pub-id></mixed-citation>
</ref>
<ref id="bib13">
<mixed-citation publication-type="journal">Theoharides TC, Doyle R, Francis K, Conti P, Kalogeromitros D. <article-title>Novel therapeutic targets for autism</article-title>. <source/>Trends Pharmacol Sci
<year>2008</year>; <volume>29</volume>: <fpage>375</fpage>–382.<pub-id pub-id-type="pmid">18606459</pub-id></mixed-citation>
</ref>
<ref id="bib14">
<mixed-citation publication-type="journal">Bauman ML. <article-title>Medical comorbidities in autism: challenges to diagnosis and treatment</article-title>. <source/>Neurotherapeutics
<year>2010</year>; <volume>7</volume>: <fpage>320</fpage>–327.<pub-id pub-id-type="pmid">20643385</pub-id></mixed-citation>
</ref>
<ref id="bib15">
<mixed-citation publication-type="journal">Olfson M, Druss BG, Marcus SC. <article-title>Trends in mental health care among children and adolescents</article-title>. <source/>N Engl J Med
<year>2015</year>; <volume>372</volume>: <fpage>2029</fpage>–2038.<pub-id pub-id-type="pmid">25992747</pub-id></mixed-citation>
</ref>
<ref id="bib16">
<mixed-citation publication-type="journal">Leigh JP, Du J. <article-title>Brief report: forecasting the economic burden of autism in 2015 and 2025 in the United States</article-title>. <source/>J Autism Dev Disord
<year>2015</year>; <volume>12</volume>: <fpage>4135</fpage>–4139.</mixed-citation>
</ref>
<ref id="bib17">
<mixed-citation publication-type="journal">Rossignol DA, Frye RE. <article-title>A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures</article-title>. <source/>Mol Psychiatry
<year>2012</year>; <volume>17</volume>: <fpage>389</fpage>–401.<pub-id pub-id-type="pmid">22143005</pub-id></mixed-citation>
</ref>
<ref id="bib18">
<mixed-citation publication-type="journal">Angelidou A, Asadi S, Alysandratos KD, Karagkouni A, Kourembanas S, Theoharides TC. <article-title>Perinatal stress, brain inflammation and risk of autism-Review and proposal</article-title>. <source/>BMC Pediatr
<year>2012</year>; <volume>12</volume>: <fpage>89</fpage>.<pub-id pub-id-type="pmid">22747567</pub-id></mixed-citation>
</ref>
<ref id="bib19">
<mixed-citation publication-type="journal">Herbert MR. <article-title>Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders</article-title>. <source/>Curr Opin Neurol
<year>2010</year>; <volume>23</volume>: <fpage>103</fpage>–110.<pub-id pub-id-type="pmid">20087183</pub-id></mixed-citation>
</ref>
<ref id="bib20">
<mixed-citation publication-type="journal">Theoharides TC, Valent P, Akin C. <article-title>Mast cells, mastocytosis, and related disorders</article-title>. <source/>N Engl J Med
<year>2015</year>; <volume>373</volume>: <fpage>163</fpage>–172.<pub-id pub-id-type="pmid">26154789</pub-id></mixed-citation>
</ref>
<ref id="bib21">
<mixed-citation publication-type="journal">Grimbaldeston MA. <article-title>Mast cell-MrgprB2: sensing secretagogues or a means to overreact</article-title>? <source/>Immunol Cell Biol
<year>2015</year>; <volume>93</volume>: <fpage>221</fpage>–223.<pub-id pub-id-type="pmid">25776987</pub-id></mixed-citation>
</ref>
<ref id="bib22">
<mixed-citation publication-type="journal">Galli SJ, Grimbaldeston M, Tsai M. <article-title>Immunomodulatory mast cells: negative, as well as positive, regulators of immunity</article-title>. <source/>Nat Rev Immunol
<year>2008</year>; <volume>8</volume>: <fpage>478</fpage>–486.<pub-id pub-id-type="pmid">18483499</pub-id></mixed-citation>
</ref>
<ref id="bib23">
<mixed-citation publication-type="journal">Theoharides TC, Alysandratos KD, Angelidou A, Delivanis DA, Sismanopoulos N, Zhang B et al. <article-title>Mast cells and inflammation</article-title>. <source/>Biochim Biophys Acta
<year>2012</year>; <volume>1822</volume>: <fpage>21</fpage>–33.<pub-id pub-id-type="pmid">21185371</pub-id></mixed-citation>
</ref>
<ref id="bib24">
<mixed-citation publication-type="journal">Chang HY, Seo JH, Kim HY, Kwon JW, Kim BJ, Kim HB et al. <article-title>Allergic diseases in preschoolers are associated with psychological and behavioural problems</article-title>. <source/>Allergy Asthma Immunol Res
<year>2013</year>; <volume>5</volume>: <fpage>315</fpage>–321.<pub-id pub-id-type="pmid">24003389</pub-id></mixed-citation>
</ref>
<ref id="bib25">
<mixed-citation publication-type="journal">Theoharides TC. <article-title>Is a subtype of autism an 'allergy of the brain'</article-title>? <source/>Clin Therap
<year>2013</year>; <volume>35</volume>: <fpage>584</fpage>–591.<pub-id pub-id-type="pmid">23688533</pub-id></mixed-citation>
</ref>
<ref id="bib26">
<mixed-citation publication-type="journal">Theoharides TC, Asadi S, Patel AB. <article-title>Focal brain inflammation and autism</article-title>. <source/>J Neuroinflammation
<year>2013</year>; <volume>10</volume>: <fpage>46</fpage>.<pub-id pub-id-type="pmid">23570274</pub-id></mixed-citation>
</ref>
<ref id="bib27">
<mixed-citation publication-type="journal">Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. <article-title>Mast cells, brain inflammation and autism</article-title>. <source/>Eur J Pharmacol
<year>2015</year>; pii <volume>S0014-2999</volume>: <fpage>00398</fpage>–2.</mixed-citation>
</ref>
<ref id="bib28">
<mixed-citation publication-type="journal">Young AM, Chakrabarti B, Roberts D, Lai MC, Suckling J, Baron-Cohen S. <article-title>From molecules to neural morphology: understanding neuroinflammation in autism spectrum condition</article-title>. <source/>Mol Autism
<year>2016</year>; <volume>7</volume>: <fpage>9</fpage>.<pub-id pub-id-type="pmid">26793298</pub-id></mixed-citation>
</ref>
<ref id="bib29">
<mixed-citation publication-type="journal">Kern JK, Geier DA, Sykes LK, Geier MR. <article-title>Relevance of neuroinflammation and encephalitis in autism</article-title>. <source/>Front Cell Neurosci
<year>2015</year>; <volume>9</volume>: <fpage>519</fpage>.<pub-id pub-id-type="pmid">26834565</pub-id></mixed-citation>
</ref>
<ref id="bib30">
<mixed-citation publication-type="journal">Zuckerman KE, Hill AP, Guion K, Voltolina L, Fombonne E. <article-title>Overweight and obesity: prevalence and correlates in a large clinical sample of children with autism spectrum disorder</article-title>. <source/>J Autism Dev Disord
<year>2014</year>; <volume>44</volume>: <fpage>1708</fpage>–1719.<pub-id pub-id-type="pmid">24488158</pub-id></mixed-citation>
</ref>
<ref id="bib31">
<mixed-citation publication-type="journal">Granich J, Lin A, Hunt A, Wray J, Dass A, Whitehouse AJ. <article-title>Obesity and associated factors in youth with an autism spectrum disorder</article-title>. <source/>Autism
<year>2016</year>; <volume>pii</volume>: <fpage>1362361315616345</fpage>; e-pub ahead of print.</mixed-citation>
</ref>
<ref id="bib32">
<mixed-citation publication-type="journal">Gregor MF, Hotamisligil GS. <article-title>Inflammatory mechanisms in obesity</article-title>. <source/>Annu Rev Immunol
<year>2011</year>; <volume>29</volume>: <fpage>415</fpage>–445.<pub-id pub-id-type="pmid">21219177</pub-id></mixed-citation>
</ref>
<ref id="bib33">
<mixed-citation publication-type="journal">Theoharides TC, Sismanopoulos N, Delivanis DA, Zhang B, Hatziagelaki EE, Kalogeromitros D. <article-title>Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity</article-title>. <source/>Trends Pharmacol Sci
<year>2011</year>; <volume>32</volume>: <fpage>534</fpage>–542.<pub-id pub-id-type="pmid">21741097</pub-id></mixed-citation>
</ref>
<ref id="bib34">
<mixed-citation publication-type="journal">Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN et al. <article-title>Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice</article-title>. <source/>Nat Med
<year>2009</year>; <volume>15</volume>: <fpage>940</fpage>–945.<pub-id pub-id-type="pmid">19633655</pub-id></mixed-citation>
</ref>
<ref id="bib35">
<mixed-citation publication-type="journal">Taildeman J, Perez-Novo CA, Rottiers I, Ferdinande L, Waeytens A, De C. <article-title>V et al. Human mast cells express leptin and leptin receptors</article-title>. <source/>Histochem Cell Biol
<year>2009</year>; <volume>131</volume>: <fpage>703</fpage>–711.<pub-id pub-id-type="pmid">19241089</pub-id></mixed-citation>
</ref>
<ref id="bib36">
<mixed-citation publication-type="journal">Zhou Y, Yu X, Chen H, Sjoberg S, Roux J, Zhang L et al. <article-title>Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages</article-title>. <source/>Cell Metab
<year>2015</year>; <volume>22</volume>: <fpage>1045</fpage>–1058.<pub-id pub-id-type="pmid">26481668</pub-id></mixed-citation>
</ref>
<ref id="bib37">
<mixed-citation publication-type="journal">Lumeng CN, Saltiel AR. <article-title>Inflammatory links between obesity and metabolic disease</article-title>. <source/>J Clin Invest
<year>2011</year>; <volume>121</volume>: <fpage>2111</fpage>–2117.<pub-id pub-id-type="pmid">21633179</pub-id></mixed-citation>
</ref>
<ref id="bib38">
<mixed-citation publication-type="journal">Ashwood P, Kwong C, Hansen R, Hertz-Picciotto I, Croen L, Krakowiak P et al. <article-title>Brief report: plasma leptin levels are elevated in autism: association with early onset phenotype</article-title>? <source/>J Autism Dev Disord
<year>2007</year>; <volume>38</volume>: <fpage>169</fpage>–175.<pub-id pub-id-type="pmid">17347881</pub-id></mixed-citation>
</ref>
<ref id="bib39">
<mixed-citation publication-type="journal">Rodriguez JI, Kern JK. <article-title>Evidence of microglial activation in autism and its possible role in brain underconnectivity</article-title>. <source/>Neuron Glia Biol
<year>2011</year>; <volume>7</volume>: <fpage>205</fpage>–213.<pub-id pub-id-type="pmid">22874006</pub-id></mixed-citation>
</ref>
<ref id="bib40">
<mixed-citation publication-type="journal">Adams-Chapman I. <article-title>Neurodevelopmental outcome of the late preterm infant</article-title>. <source/>Clin Perinatol
<year>2006</year>; <volume>33</volume>: <fpage>947</fpage>–964.<pub-id pub-id-type="pmid">17148014</pub-id></mixed-citation>
</ref>
<ref id="bib41">
<mixed-citation publication-type="journal">Volpe JJ. <article-title>The encephalopathy of prematurity—brain injury and impaired brain development inextricably intertwined</article-title>. <source/>Semin Pediatr Neurol
<year>2009</year>; <volume>16</volume>: <fpage>167</fpage>–178.<pub-id pub-id-type="pmid">19945651</pub-id></mixed-citation>
</ref>
<ref id="bib42">
<mixed-citation publication-type="journal">Johnson S, Marlow N. <article-title>Preterm birth and childhood psychiatric disorders</article-title>. <source/>Pediatr Res
<year>2011</year>; <volume>5</volume>, Pt 2 <fpage>11 R</fpage>–18R.</mixed-citation>
</ref>
<ref id="bib43">
<mixed-citation publication-type="journal">Limperopoulos C, Bassan H, Sullivan NR, Soul JS, Robertson RL Jr, Moore M et al. <article-title>Positive screening for autism in ex-preterm infants: prevalence and risk factors</article-title>. <source/>Pediatrics
<year>2008</year>; <volume>121</volume>: <fpage>758</fpage>–765.<pub-id pub-id-type="pmid">18381541</pub-id></mixed-citation>
</ref>
<ref id="bib44">
<mixed-citation publication-type="journal">Kleinman JM, Robins DL, Ventola PE, Pandey J, Boorstein HC, Esser EL et al. <article-title>The modified checklist for autism in toddlers: a follow-up study investigating the early detection of autism spectrum disorders</article-title>. <source/>J Autism Dev Disord
<year>2008</year>; <volume>38</volume>: <fpage>827</fpage>–839.<pub-id pub-id-type="pmid">17882539</pub-id></mixed-citation>
</ref>
<ref id="bib45">
<mixed-citation publication-type="journal">Maimburg RD, Vaeth M. <article-title>Perinatal risk factors and infantile autism</article-title>. <source/>Acta Psychiatr Scand
<year>2006</year>; <volume>114</volume>: <fpage>257</fpage>–264.<pub-id pub-id-type="pmid">16968363</pub-id></mixed-citation>
</ref>
<ref id="bib46">
<mixed-citation publication-type="journal">Hultman CM, Sparen P, Cnattingius S. <article-title>Perinatal risk factors for infantile autism</article-title>. <source/>Epidemiology
<year>2002</year>; <volume>13</volume>: <fpage>417</fpage>–423.<pub-id pub-id-type="pmid">12094096</pub-id></mixed-citation>
</ref>
<ref id="bib47">
<mixed-citation publication-type="journal">Ronald A, Pennell CE, Whitehouse AJ. <article-title>Prenatal maternal stress associated with ADHD and autistic traits in early childhood</article-title>. <source/>Front Psychol
<year>2010</year>; <volume>1</volume>: <fpage>223</fpage>.<pub-id pub-id-type="pmid">21833278</pub-id></mixed-citation>
</ref>
<ref id="bib48">
<mixed-citation publication-type="journal">Roberts AL, Koenen KC, Lyall K, Robinson EB, Weisskopf MG. <article-title>Association of autistic traits in adulthood with childhood abuse, interpersonal victimization, and posttraumatic stress</article-title>. <source/>Child Abuse Negl
<year>2015</year>; <volume>45</volume>: <fpage>135</fpage>–142.<pub-id pub-id-type="pmid">25957197</pub-id></mixed-citation>
</ref>
<ref id="bib49">
<mixed-citation publication-type="journal">Roberts AL, Lyall K, Rich-Edwards JW, Ascherio A, Weisskopf MG. <article-title>Association of maternal exposure to childhood abuse with elevated risk for autism in offspring</article-title>. <source/>JAMA Psychiatry
<year>2013</year>; <volume>70</volume>: <fpage>508</fpage>–515.<pub-id pub-id-type="pmid">23553149</pub-id></mixed-citation>
</ref>
<ref id="bib50">
<mixed-citation publication-type="journal">Vasa RA, Mazurek MO. <article-title>An update on anxiety in youth with autism spectrum disorders</article-title>. <source/>Curr Opin Psychiatry
<year>2015</year>; <volume>28</volume>: <fpage>83</fpage>–90.<pub-id pub-id-type="pmid">25602249</pub-id></mixed-citation>
</ref>
<ref id="bib51">
<mixed-citation publication-type="journal">van Steensel FJ, Bogels SM, Perrin S. <article-title>Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis</article-title>. <source/>Clin Child Fam Psychol Rev
<year>2011</year>; <volume>14</volume>: <fpage>302</fpage>–317.<pub-id pub-id-type="pmid">21735077</pub-id></mixed-citation>
</ref>
<ref id="bib52">
<mixed-citation publication-type="journal">Rodgers J, Glod M, Connolly B, McConachie H. <article-title>The relationship between anxiety and repetitive behaviours in autism spectrum disorder</article-title>. <source/>J Autism Dev Disord
<year>2012</year>; <volume>42</volume>: <fpage>2404</fpage>–2409.<pub-id pub-id-type="pmid">22527704</pub-id></mixed-citation>
</ref>
<ref id="bib53">
<mixed-citation publication-type="journal">Donelan J, Boucher W, Papadopoulou N, Lytinas M, Papaliodis D, Theoharides TC. <article-title>Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process</article-title>. <source/>Proc Natl Acad Sci USA
<year>2006</year>; <volume>103</volume>: <fpage>7759</fpage>–7764.<pub-id pub-id-type="pmid">16682628</pub-id></mixed-citation>
</ref>
<ref id="bib54">
<mixed-citation publication-type="journal">Lantos TA, Palkovits M, Rostene W, Berod A. <article-title>Neurotensin receptors in the human amygdaloid complex. Topographical and quantitative autoradiographic study</article-title>. <source/>J Chem Neuroanat
<year>1996</year>; <volume>11</volume>: <fpage>209</fpage>–217.<pub-id pub-id-type="pmid">8906462</pub-id></mixed-citation>
</ref>
<ref id="bib55">
<mixed-citation publication-type="journal">Najimi M, Sarrieau A, Kopp N, Chigr F. <article-title>An autoradiographic study of neurotensin receptors in the human hypothalamus</article-title>. <source/>Acta Histochem
<year>2014</year>; <volume>116</volume>: <fpage>382</fpage>–389.<pub-id pub-id-type="pmid">24144485</pub-id></mixed-citation>
</ref>
<ref id="bib56">
<mixed-citation publication-type="journal">Esposito P, Chandler N, Kandere-Grzybowska K, Basu S, Jacobson S, Connolly R et al. <article-title>Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress</article-title>. <source/>J Pharmacol Exp Ther
<year>2002</year>; <volume>303</volume>: <fpage>1061</fpage>–1066.<pub-id pub-id-type="pmid">12438528</pub-id></mixed-citation>
</ref>
<ref id="bib57">
<mixed-citation publication-type="journal">Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL et al. <article-title>Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor</article-title>. <source/>J Immunol
<year>2005</year>; <volume>174</volume>: <fpage>7665</fpage>–7675.<pub-id pub-id-type="pmid">15944267</pub-id></mixed-citation>
</ref>
<ref id="bib58">
<mixed-citation publication-type="journal">Theoharides TC, Konstantinidou A. <article-title>Corticotropin-releasing hormone and the blood-brain-barrier</article-title>. <source/>Front Biosci
<year>2007</year>; <volume>12</volume>: <fpage>1615</fpage>–1628.<pub-id pub-id-type="pmid">17127408</pub-id></mixed-citation>
</ref>
<ref id="bib59">
<mixed-citation publication-type="journal">Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, varez-Twose I et al. <article-title>Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology</article-title>. <source/>J Allergy Clin Immunol
<year>2016</year>; <volume>137</volume>: <fpage>35</fpage>–45.<pub-id pub-id-type="pmid">26476479</pub-id></mixed-citation>
</ref>
<ref id="bib60">
<mixed-citation publication-type="journal">Theoharides TC, Enakuua S, Sismanopoulos N, Papadimas E, Angelidou A, Alysandratos K. <article-title>Stress contributes to asthma worsening through mast cell activation</article-title>. <source/>Ann Allergy Asthma Immunol
<year>2012</year>; <volume>109</volume>: <fpage>14</fpage>–19.<pub-id pub-id-type="pmid">22727152</pub-id></mixed-citation>
</ref>
<ref id="bib61">
<mixed-citation publication-type="journal">Karagkouni A, Alevizos M, Theoharides TC. <article-title>Effect of stress on brain inflammation and multiple sclerosis</article-title>. <source/>Autoimmun Rev
<year>2013</year>; <volume>12</volume>: <fpage>947</fpage>–953.<pub-id pub-id-type="pmid">23537508</pub-id></mixed-citation>
</ref>
<ref id="bib62">
<mixed-citation publication-type="journal">Lyall K, Van de Water J, Ashwood P, Hertz-Picciotto I. <article-title>Asthma and allergies in children with autism spectrum disorders: results from the CHARGE study</article-title>. <source/>Autism Res
<year>2015</year>; <volume>8</volume>: <fpage>567</fpage>–574.<pub-id pub-id-type="pmid">25722050</pub-id></mixed-citation>
</ref>
<ref id="bib63">
<mixed-citation publication-type="journal">Chen SW, Zhong XS, Jiang LN, Zheng XY, Xiong YQ, Ma SJ et al. <article-title>Maternal autoimmune diseases and the risk of autism spectrum disorders in offspring: a systematic review and meta-analysis</article-title>. <source/>Behav Brain Res
<year>2015</year>; <volume>296</volume>: <fpage>61</fpage>–69.<pub-id pub-id-type="pmid">26327239</pub-id></mixed-citation>
</ref>
<ref id="bib64">
<mixed-citation publication-type="journal">Kotey S, Ertel K, Whitcomb B. <article-title>Co-occurrence of autism and asthma in a nationally-representative sample of children in the United States</article-title>. <source/>J Autism Dev Disord
<year>2014</year>; <volume>44</volume>: <fpage>3083</fpage>–3088.<pub-id pub-id-type="pmid">24997632</pub-id></mixed-citation>
</ref>
<ref id="bib65">
<mixed-citation publication-type="journal">Theoharides TC. <article-title>Autism spectrum disorders and mastocytosis</article-title>. <source/>Int J Immunopathol Pharmacol
<year>2009</year>; <volume>22</volume>: <fpage>859</fpage>–865.<pub-id pub-id-type="pmid">20074449</pub-id></mixed-citation>
</ref>
<ref id="bib66">
<mixed-citation publication-type="journal">Douwes J, Brooks C, van DC, Pearce N. <article-title>Importance of allergy in asthma: an epidemiologic perspective</article-title>. <source/>Curr Allergy Asthma Rep
<year>2011</year>; <volume>11</volume>: <fpage>434</fpage>–444.<pub-id pub-id-type="pmid">21792637</pub-id></mixed-citation>
</ref>
<ref id="bib67">
<mixed-citation publication-type="journal">Vermeersch P, Bossuyt X. <article-title>Prevalence and clinical significance of rare antinuclear antibody patterns</article-title>. <source/>Autoimmun Rev
<year>2013</year>; <volume>12</volume>: <fpage>998</fpage>–1003.<pub-id pub-id-type="pmid">23583982</pub-id></mixed-citation>
</ref>
<ref id="bib68">
<mixed-citation publication-type="journal">Hayter SM, Cook MC. <article-title>Updated assessment of the prevalence, spectrum and case definition of autoimmune disease</article-title>. <source/>Autoimmun Rev
<year>2012</year>; <volume>11</volume>: <fpage>754</fpage>–765.<pub-id pub-id-type="pmid">22387972</pub-id></mixed-citation>
</ref>
<ref id="bib69">
<mixed-citation publication-type="journal">Gurney JG, McPheeters ML, Davis MM. <article-title>Parental report of health conditions and health care use among children with and without autism: National Survey of Children's Health</article-title>. <source/>Arch Pediatr Adolesc Med
<year>2006</year>; <volume>160</volume>: <fpage>825</fpage>–830.<pub-id pub-id-type="pmid">16894082</pub-id></mixed-citation>
</ref>
<ref id="bib70">
<mixed-citation publication-type="journal">Magalhaes ES, Pinto-Mariz F, Bastos-Pinto S, Pontes AT, Prado EA, Deazevedo LC. <article-title>Immune allergic response in Asperger syndrome</article-title>. <source/>J Neuroimmunol
<year>2009</year>; <volume>216</volume>: <fpage>108</fpage>–112.<pub-id pub-id-type="pmid">19840888</pub-id></mixed-citation>
</ref>
<ref id="bib71">
<mixed-citation publication-type="journal">Bakkaloglu B, Anlar B, Anlar FY, Oktem F, Pehlivanturk B, Unal F et al. <article-title>Atopic features in early childhood autism</article-title>. <source/>Eur J Paediatr Neurol
<year>2008</year>; <volume>12</volume>: <fpage>476</fpage>–479.<pub-id pub-id-type="pmid">18272414</pub-id></mixed-citation>
</ref>
<ref id="bib72">
<mixed-citation publication-type="journal">Jyonouchi H. <article-title>Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic</article-title>. <source/>Exp Rev Clin Immunol
<year>2010</year>; <volume>6</volume>: <fpage>397</fpage>–411.</mixed-citation>
</ref>
<ref id="bib73">
<mixed-citation publication-type="journal">Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M et al. <article-title>Brief report: "allergic symptoms" in children with autism spectrum disorders. More than meets the eye</article-title>?. <source/>J Autism Dev Disord
<year>2011</year>; <volume>41</volume>: <fpage>1579</fpage>–1585.<pub-id pub-id-type="pmid">21210299</pub-id></mixed-citation>
</ref>
<ref id="bib74">
<mixed-citation publication-type="journal">Yaghmaie P, Koudelka CW, Simpson EL. <article-title>Mental health comorbidity in patients with atopic dermatitis</article-title>. <source/>J Allergy Clin Immunol
<year>2013</year>; <volume>131</volume>: <fpage>428</fpage>–433.<pub-id pub-id-type="pmid">23245818</pub-id></mixed-citation>
</ref>
<ref id="bib75">
<mixed-citation publication-type="journal">Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH et al. <article-title>Is atopy in early childhood a risk factor for ADHD and ASD? a longitudinal study</article-title>. <source/>J Psychosom Res
<year>2014</year>; <volume>77</volume>: <fpage>316</fpage>–321.<pub-id pub-id-type="pmid">25280829</pub-id></mixed-citation>
</ref>
<ref id="bib76">
<mixed-citation publication-type="journal">Zerbo O, Leong A, Barcellos L, Bernal P, Fireman B, Croen LA. <article-title>Immune mediated conditions in autism spectrum disorders</article-title>. <source/>Brain Behav Immun
<year>2015</year>; <volume>46</volume>: <fpage>232</fpage>–236.<pub-id pub-id-type="pmid">25681541</pub-id></mixed-citation>
</ref>
<ref id="bib77">
<mixed-citation publication-type="journal">de Theije CG, Wu J, Koelink PJ, Korte-Bouws GA, Borre Y, Kas MJ et al. <article-title>Autistic-like behavioural and neurochemical changes in a mouse model of food allergy</article-title>. <source/>Behav Brain Res
<year>2014</year>; <volume>261</volume>: <fpage>265</fpage>–274.<pub-id pub-id-type="pmid">24333575</pub-id></mixed-citation>
</ref>
<ref id="bib78">
<mixed-citation publication-type="journal">Saluja R, Metz M, Maurer M. <article-title>Role and relevance of mast cells in fungal infections</article-title>. <source/>Front Immunol
<year>2012</year>; <volume>3</volume>: <fpage>146</fpage>.<pub-id pub-id-type="pmid">22707950</pub-id></mixed-citation>
</ref>
<ref id="bib79">
<mixed-citation publication-type="journal">Urb M, Pouliot P, Gravelat FN, Olivier M, Sheppard DC. <article-title><italic>Aspergillus fumigatus</italic> induces immunoglobulin E-independent mast cell degranulation</article-title>. <source/>J Infect Dis
<year>2009</year>; <volume>200</volume>: <fpage>464</fpage>–472.<pub-id pub-id-type="pmid">19527167</pub-id></mixed-citation>
</ref>
<ref id="bib80">
<mixed-citation publication-type="journal">Olynych TJ, Jakeman DL, Marshall JS. <article-title>Fungal zymosan induces leukotriene production by human mast cells through a dectin-1-dependent mechanism</article-title>. <source/>J Allergy Clin Immunol
<year>2006</year>; <volume>118</volume>: <fpage>837</fpage>–843.<pub-id pub-id-type="pmid">17030235</pub-id></mixed-citation>
</ref>
<ref id="bib81">
<mixed-citation publication-type="journal">Kempuraj D, Asadi S, Zhang B, Manola A, Hogan J, Peterson E et al. <article-title>Mercury induces inflammatory mediator release from human mast cells</article-title>. <source/>J Neuroinflammation
<year>2010</year>; <volume>7</volume>: <fpage>20</fpage>.<pub-id pub-id-type="pmid">20222982</pub-id></mixed-citation>
</ref>
<ref id="bib82">
<mixed-citation publication-type="journal">McKee AS, Munks MW, MacLeod MK, Fleenor CJ, van RN, Kappler JW et al. <article-title>Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity</article-title>. <source/>J Immunol
<year>2009</year>; <volume>183</volume>: <fpage>4403</fpage>–4414.<pub-id pub-id-type="pmid">19734227</pub-id></mixed-citation>
</ref>
<ref id="bib83">
<mixed-citation publication-type="journal">Goines PE, Ashwood P. <article-title>Cytokine dysregulation in autism spectrum disorders (ASD): possible role of the environment</article-title>. <source/>Neurotoxicol Teratol
<year>2012</year>; <volume>36</volume>: <fpage>67</fpage>–81.<pub-id pub-id-type="pmid">22918031</pub-id></mixed-citation>
</ref>
<ref id="bib84">
<mixed-citation publication-type="journal">Rossignol DA, Genuis SJ, Frye RE. <article-title>Environmental toxicants and autism spectrum disorders: a systematic review</article-title>. <source/>Transl Psychiatry
<year>2014</year>; <volume>4</volume>: <fpage>e360</fpage>.<pub-id pub-id-type="pmid">24518398</pub-id></mixed-citation>
</ref>
<ref id="bib85">
<mixed-citation publication-type="journal">Ming X, Brimacombe M, Malek JH, Jani N, Wagner GC. <article-title>Autism spectrum disorders and identified toxic land fills: co-occurrence across States</article-title>. <source/>Environ Health Insights
<year>2008</year>; <volume>2</volume>: <fpage>55</fpage>–59.<pub-id pub-id-type="pmid">21572830</pub-id></mixed-citation>
</ref>
<ref id="bib86">
<mixed-citation publication-type="journal">Wong CT, Wais J, Crawford DA. <article-title>Prenatal exposure to common environmental factors affects brain lipids and increases risk of developing autism spectrum disorders</article-title>. <source/>Eur J Neurosci
<year>2015</year>; <volume>42</volume>: <fpage>2742</fpage>–2760.<pub-id pub-id-type="pmid">26215319</pub-id></mixed-citation>
</ref>
<ref id="bib87">
<mixed-citation publication-type="journal">Heilbrun LP, Palmer RF, Jaen CR, Svoboda MD, Miller CS, Perkins J. <article-title>Maternal chemical and drug intolerances: potential risk factors for autism and attention deficit hyperactivity disorder (ADHD)</article-title>. <source/>J Am Board Fam Med
<year>2015</year>; <volume>28</volume>: <fpage>461</fpage>–470.<pub-id pub-id-type="pmid">26152436</pub-id></mixed-citation>
</ref>
<ref id="bib88">
<mixed-citation publication-type="journal">Jedrychowski W, Maugeri U, Perera F, Stigter L, Jankowski J, Butscher M et al. <article-title>Cognitive function of 6-year old children exposed to mold-contaminated homes in early postnatal period. Prospective birth cohort study in Poland</article-title>. <source/>Physiol Behav
<year>2011</year>; <volume>104</volume>: <fpage>989</fpage>–995.<pub-id pub-id-type="pmid">21763705</pub-id></mixed-citation>
</ref>
<ref id="bib89">
<mixed-citation publication-type="journal">Empting LD. <article-title>Neurologic and neuropsychiatric syndrome features of mold and mycotoxin exposure</article-title>. <source/>Toxicol Ind Health
<year>2009</year>; <volume>25</volume>: <fpage>577</fpage>–581.<pub-id pub-id-type="pmid">19854819</pub-id></mixed-citation>
</ref>
<ref id="bib90">
<mixed-citation publication-type="journal">Bernard S, Enayati A, Roger H, Binstock T, Redwood L. <article-title>The role of mercury in the pathogenesis of autism</article-title>. <source/>Mol Psychiatry
<year>2002</year>; <volume>7</volume>(Suppl 2): <fpage>S42</fpage>–S43.<pub-id pub-id-type="pmid">12142947</pub-id></mixed-citation>
</ref>
<ref id="bib91">
<mixed-citation publication-type="journal">Geier DA, Kern JK, King PG, Sykes LK, Geier MR. <article-title>Hair toxic metal concentrations and autism spectrum disorder severity in young children</article-title>. <source/>Int J Environ Res Public Health
<year>2012</year>; <volume>9</volume>: <fpage>4486</fpage>–4497.<pub-id pub-id-type="pmid">23222182</pub-id></mixed-citation>
</ref>
<ref id="bib92">
<mixed-citation publication-type="journal">Tomljenovic L, Shaw CA. <article-title>Do aluminum vaccine adjuvants contribute to the rising prevalence of autism</article-title>? <source/>J Inorg Biochem
<year>2011</year>; <volume>105</volume>: <fpage>1489</fpage>–1499.<pub-id pub-id-type="pmid">22099159</pub-id></mixed-citation>
</ref>
<ref id="bib93">
<mixed-citation publication-type="journal">Kumar V, Bal A, Gill KD. <article-title>Aluminium-induced oxidative DNA damage recognition and cell-cycle disruption in different regions of rat brain</article-title>. <source/>Toxicology
<year>2009</year>; <volume>264</volume>: <fpage>137</fpage>–144.<pub-id pub-id-type="pmid">19464335</pub-id></mixed-citation>
</ref>
<ref id="bib94">
<mixed-citation publication-type="journal">Sood PK, Nahar U, Nehru B. <article-title>Stress proteins and glial cell functions during chronic aluminium exposures: protective role of curcumin</article-title>. <source/>Neurochem Res
<year>2012</year>; <volume>37</volume>: <fpage>639</fpage>–646.<pub-id pub-id-type="pmid">22130689</pub-id></mixed-citation>
</ref>
<ref id="bib95">
<mixed-citation publication-type="journal">Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K et al. <article-title>DNA released from dying host cells mediates aluminum adjuvant activity</article-title>. <source/>Nat Med
<year>2011</year>; <volume>17</volume>: <fpage>996</fpage>–1002.<pub-id pub-id-type="pmid">21765404</pub-id></mixed-citation>
</ref>
<ref id="bib96">
<mixed-citation publication-type="journal">Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W et al. <article-title>Circulating mitochondrial DAMPs cause inflammatory responses to injury</article-title>. <source/>Nature
<year>2010</year>; <volume>464</volume>: <fpage>104</fpage>–107.<pub-id pub-id-type="pmid">20203610</pub-id></mixed-citation>
</ref>
<ref id="bib97">
<mixed-citation publication-type="journal">Galli SJ, Tsai M. <article-title>Mast cells in allergy and infection: versatile effector and regulatory cells in innate and adaptive immunity</article-title>. <source/>Eur J Immunol
<year>2010</year>; <volume>40</volume>: <fpage>1843</fpage>–1851.<pub-id pub-id-type="pmid">20583030</pub-id></mixed-citation>
</ref>
<ref id="bib98">
<mixed-citation publication-type="journal">Abraham SN St, John AL. <article-title>Mast cell-orchestrated immunity to pathogens</article-title>. <source/>Nat Rev Immunol
<year>2010</year>; <volume>10</volume>: <fpage>440</fpage>–452.<pub-id pub-id-type="pmid">20498670</pub-id></mixed-citation>
</ref>
<ref id="bib99">
<mixed-citation publication-type="journal">Sandig H, Bulfone-Paus S. <article-title>TLR signaling in mast cells: common and unique features</article-title>. <source/>Front Immunol
<year>2012</year>; <volume>3</volume>: <fpage>185</fpage>.<pub-id pub-id-type="pmid">22783258</pub-id></mixed-citation>
</ref>
<ref id="bib100">
<mixed-citation publication-type="journal">Zhang B, Asadi S, Weng Z, Sismanopoulos N, Theoharides TC. <article-title>Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions</article-title>. <source/>PLoS One
<year>2012</year>; <volume>7</volume>: <fpage>e49767</fpage>.<pub-id pub-id-type="pmid">23284625</pub-id></mixed-citation>
</ref>
<ref id="bib101">
<mixed-citation publication-type="journal">Asadi S, Theoharides TC. <article-title>Corticotropin-releasing hormone and extracellular mitochondria augment IgE-stimulated human mast-cell vascular endothelial growth factor release, which is inhibited by luteolin</article-title>. <source/>J Neuroinflammation
<year>2012</year>; <volume>9</volume>: <fpage>85</fpage>.<pub-id pub-id-type="pmid">22559745</pub-id></mixed-citation>
</ref>
<ref id="bib102">
<mixed-citation publication-type="journal">Theoharides TC, Asadi S, Panagiotidou S, Weng Z. <article-title>The "missing link" in autoimmunity and autism: Extracellular mitochondrial components secreted from activated live mast cells</article-title>. <source/>Autoimmun Rev
<year>2013</year>; <volume>12</volume>: <fpage>1136</fpage>–1142.<pub-id pub-id-type="pmid">23831684</pub-id></mixed-citation>
</ref>
<ref id="bib103">
<mixed-citation publication-type="journal">Lauritzen KH, Moldestad O, Eide L, Carlsen H, Nesse G, Storm JF et al. <article-title>Mitochondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegeneration, and impaired behavior</article-title>. <source/>Mol Cell Biol
<year>2010</year>; <volume>30</volume>: <fpage>1357</fpage>–1367.<pub-id pub-id-type="pmid">20065039</pub-id></mixed-citation>
</ref>
<ref id="bib104">
<mixed-citation publication-type="journal">Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S et al. <article-title>Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children</article-title>. <source/>J Neuroinflammation
<year>2010</year>; <volume>7</volume>: <fpage>80</fpage>.<pub-id pub-id-type="pmid">21083929</pub-id></mixed-citation>
</ref>
<ref id="bib105">
<mixed-citation publication-type="journal">Rossignol DA, Frye RE. <article-title>Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis</article-title>. <source/>Mol Psychiatry
<year>2012</year>; <volume>17</volume>: <fpage>290</fpage>–314.<pub-id pub-id-type="pmid">21263444</pub-id></mixed-citation>
</ref>
<ref id="bib106">
<mixed-citation publication-type="journal">Galli SJ, Tsai M, Piliponsky AM. <article-title>The development of allergic inflammation</article-title>. <source/>Nature
<year>2008</year>; <volume>454</volume>: <fpage>445</fpage>–454.<pub-id pub-id-type="pmid">18650915</pub-id></mixed-citation>
</ref>
<ref id="bib107">
<mixed-citation publication-type="journal">Hagberg H, Gressens P, Mallard C. <article-title>Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults</article-title>. <source/>Ann Neurol
<year>2012</year>; <volume>71</volume>: <fpage>444</fpage>–457.<pub-id pub-id-type="pmid">22334391</pub-id></mixed-citation>
</ref>
<ref id="bib108">
<mixed-citation publication-type="journal">Jones KA, Thomsen C. <article-title>The role of the innate immune system in psychiatric disorders</article-title>. <source/>Mol Cell Neurosci
<year>2013</year>; <volume>53</volume>: <fpage>52</fpage>–62.<pub-id pub-id-type="pmid">23064447</pub-id></mixed-citation>
</ref>
<ref id="bib109">
<mixed-citation publication-type="journal">Chavarria A, Alcocer-Varela J. <article-title>Is damage in central nervous system due to inflammation</article-title>? <source/>Autoimmun Rev
<year>2004</year>; <volume>3</volume>: <fpage>251</fpage>–260.<pub-id pub-id-type="pmid">15246020</pub-id></mixed-citation>
</ref>
<ref id="bib110">
<mixed-citation publication-type="journal">Le Belle JE, Sperry J, Ngo A, Ghochani Y, Laks DR, Lopez-Aranda M et al. <article-title>Maternal inflammation contributes to brain overgrowth and autism-associated behaviors through altered redox signaling in stem and progenitor cells</article-title>. <source/>Stem Cell Rep
<year>2014</year>; <volume>3</volume>: <fpage>725</fpage>–734.</mixed-citation>
</ref>
<ref id="bib111">
<mixed-citation publication-type="journal">Onore C, Careaga M, Ashwood P. <article-title>The role of immune dysfunction in the pathophysiology of autism</article-title>. <source/>Brain Behav Immun
<year>2012</year>; <volume>26</volume>: <fpage>383</fpage>–392.<pub-id pub-id-type="pmid">21906670</pub-id></mixed-citation>
</ref>
<ref id="bib112">
<mixed-citation publication-type="journal">Estes ML, McAllister AK. <article-title>Immune mediators in the brain and peripheral tissues in autism spectrum disorder</article-title>. <source/>Nat Rev Neurosci
<year>2015</year>; <volume>16</volume>: <fpage>469</fpage>–486.<pub-id pub-id-type="pmid">26189694</pub-id></mixed-citation>
</ref>
<ref id="bib113">
<mixed-citation publication-type="journal">Bauman MD, Iosif AM, Smith SE, Bregere C, Amaral DG, Patterson PH. <article-title>Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring</article-title>. <source/>Biol Psychiatry
<year>2014</year>; <volume>75</volume>: <fpage>332</fpage>–341.<pub-id pub-id-type="pmid">24011823</pub-id></mixed-citation>
</ref>
<ref id="bib114">
<mixed-citation publication-type="journal">Gesundheit B, Rosenzweig JP, Naor D, Lerer B, Zachor DA, Prochazka V et al. <article-title>Immunological and autoimmune considerations of Autism Spectrum Disorders</article-title>. <source/>J Autoimmun
<year>2013</year>; <volume>44</volume>: <fpage>1</fpage>–7.<pub-id pub-id-type="pmid">23867105</pub-id></mixed-citation>
</ref>
<ref id="bib115">
<mixed-citation publication-type="journal">Braunschweig D, Van de Water J. <article-title>Maternal autoantibodies in autism</article-title>. <source/>Arch Neurol
<year>2012</year>; <volume>69</volume>: <fpage>693</fpage>–699.<pub-id pub-id-type="pmid">22689191</pub-id></mixed-citation>
</ref>
<ref id="bib116">
<mixed-citation publication-type="journal">Zimmerman AW, Connors SL, Matteson KJ, Lee LC, Singer HS, Castaneda JA et al. <article-title>Maternal antibrain antibodies in autism</article-title>. <source/>Brain Behav Immun
<year>2007</year>; <volume>21</volume>: <fpage>351</fpage>–357.<pub-id pub-id-type="pmid">17029701</pub-id></mixed-citation>
</ref>
<ref id="bib117">
<mixed-citation publication-type="journal">Rossi CC, Van de Water J, Rogers SJ, Amaral DG. <article-title>Detection of plasma autoantibodies to brain tissue in young children with and without autism spectrum disorders</article-title>. <source/>Brain Behav Immun
<year>2011</year>; <volume>25</volume>: <fpage>1123</fpage>–1135.<pub-id pub-id-type="pmid">21420487</pub-id></mixed-citation>
</ref>
<ref id="bib118">
<mixed-citation publication-type="journal">Ribatti D. <article-title>The crucial role of mast cells in blood-brain barrier alterations</article-title>. <source/>Exp Cell Res
<year>2015</year>; <volume>338</volume>: <fpage>119</fpage>–125.<pub-id pub-id-type="pmid">26004870</pub-id></mixed-citation>
</ref>
<ref id="bib119">
<mixed-citation publication-type="journal">Mostafa GA, Al-Ayadhi LY. <article-title>The possible relationship between allergic manifestations and elevated serum levels of brain specific auto-antibodies in autistic children</article-title>. <source/>J Neuroimmunol
<year>2013</year>; <volume>261</volume>: <fpage>77</fpage>–81.<pub-id pub-id-type="pmid">23726766</pub-id></mixed-citation>
</ref>
<ref id="bib120">
<mixed-citation publication-type="journal">Zimmerman AW, Jyonouchi H, Comi AM, Connors SL, Milstien S, Varsou A et al. <article-title>Cerebrospinal fluid and serum markers of inflammation in autism</article-title>. <source/>Pediatr Neurol
<year>2005</year>; <volume>33</volume>: <fpage>195</fpage>–201.<pub-id pub-id-type="pmid">16139734</pub-id></mixed-citation>
</ref>
<ref id="bib121">
<mixed-citation publication-type="journal">Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM et al. <article-title>Elevated immune response in the brain of autistic patients</article-title>. <source/>J Neuroimmunol
<year>2009</year>; <volume>207</volume>: <fpage>111</fpage>–116.<pub-id pub-id-type="pmid">19157572</pub-id></mixed-citation>
</ref>
<ref id="bib122">
<mixed-citation publication-type="journal">Tsilioni I, Taliou A, Francis K, Theoharides TC. <article-title>Children with Autism Spectrum Disorders, who improved with a luteolin containing dietary formulation, show reduced serum levels of TNF and IL-6</article-title>. <source/>Transl Psychiatry
<year>2015</year>; <volume>5</volume>: <fpage>e647</fpage>.<pub-id pub-id-type="pmid">26418275</pub-id></mixed-citation>
</ref>
<ref id="bib123">
<mixed-citation publication-type="journal">Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. <article-title>Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome</article-title>. <source/>Brain Behav Immun
<year>2011</year>; <volume>25</volume>: <fpage>40</fpage>–45.<pub-id pub-id-type="pmid">20705131</pub-id></mixed-citation>
</ref>
<ref id="bib124">
<mixed-citation publication-type="other">Krakowiak P, Goines PE, Tancredi DJ, Ashwood P, Hansen RL, Hertz-Picciotto I et al. <article-title>Neonatal cytokine profiles asAnchorsociated with autism spectrum disorder</article-title>. <source/>Biol Psychiatry
<year>2015</year>; S0006-3223(15)00655-1.</mixed-citation>
</ref>
<ref id="bib125">
<mixed-citation publication-type="journal">Zerbo O, Yoshida C, Grether JK, Van de Water J, Ashwood P, Delorenze GN et al. <article-title>Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study</article-title>. <source/>J Neuroinflammation
<year>2014</year>; <volume>11</volume>: <fpage>113</fpage>.<pub-id pub-id-type="pmid">24951035</pub-id></mixed-citation>
</ref>
<ref id="bib126">
<mixed-citation publication-type="journal">Goines PE, Croen LA, Braunschweig D, Yoshida CK, Grether J, Hansen R et al. <article-title>Increased midgestational IFN-gamma, IL-4 and IL-5 in women bearing a child with autism: a case-control study</article-title>. <source/>Mol Autism
<year>2011</year>; <volume>2</volume>: <fpage>13</fpage>.<pub-id pub-id-type="pmid">21810230</pub-id></mixed-citation>
</ref>
<ref id="bib127">
<mixed-citation publication-type="journal">Nakae S, Suto H, Berry GJ, Galli SJ. <article-title>Mast cell-derived TNF can promote Th17 cell-dependent neutrophil recruitment in ovalbumin-challenged OTII mice</article-title>. <source/>Blood
<year>2007</year>; <volume>109</volume>: <fpage>3640</fpage>–3648.<pub-id pub-id-type="pmid">17197430</pub-id></mixed-citation>
</ref>
<ref id="bib128">
<mixed-citation publication-type="journal">Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N et al. <article-title>Intersection of population variation and autoimmunity genetics in human T cell activation</article-title>. <source/>Science
<year>2014</year>; <volume>345</volume>: <fpage>1254665</fpage>.<pub-id pub-id-type="pmid">25214635</pub-id></mixed-citation>
</ref>
<ref id="bib129">
<mixed-citation publication-type="journal">Chen X, Churchill MJ, Nagar KK, Tailor YH, Chu T, Rush BS et al. <article-title>IL-17 producing mast cells promote the expansion of myeloid-derived suppressor cells in a mouse allergy model of colorectal cancer</article-title>. <source/>Oncotarget
<year>2015</year>; <volume>6</volume>: <fpage>32966</fpage>–32979.<pub-id pub-id-type="pmid">26429861</pub-id></mixed-citation>
</ref>
<ref id="bib130">
<mixed-citation publication-type="journal">Al-Ayadhi LY, Mostafa GA. <article-title>Elevated serum levels of interleukin-17 A in children with autism</article-title>. <source/>J Neuroinflammation
<year>2012</year>; <volume>9</volume>: <fpage>158</fpage>.<pub-id pub-id-type="pmid">22748016</pub-id></mixed-citation>
</ref>
<ref id="bib131">
<mixed-citation publication-type="journal">Akintunde ME, Rose M, Krakowiak P, Heuer L, Ashwood P, Hansen R et al. <article-title>Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma</article-title>. <source/>J Neuroimmunol
<year>2015</year>; <volume>286</volume>: <fpage>33</fpage>–41.<pub-id pub-id-type="pmid">26298322</pub-id></mixed-citation>
</ref>
<ref id="bib132">
<mixed-citation publication-type="journal">Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim SV et al. <article-title>The maternal interleukin-17a pathway in mice promotes autismlike phenotypes in offspring</article-title>. <source/>Science
<year>2016</year>; <volume>pii</volume>: <fpage>aad0314</fpage>.</mixed-citation>
</ref>
<ref id="bib133">
<mixed-citation publication-type="journal">Hsiao EY, McBride SW, Chow J, Mazmanian SK, Patterson PH. <article-title>Modeling an autism risk factor in mice leads to permanent immune dysregulation</article-title>. <source/>Proc Natl Acad Sci USA
<year>2012</year>; <volume>109</volume>: <fpage>12776</fpage>–12781.<pub-id pub-id-type="pmid">22802640</pub-id></mixed-citation>
</ref>
<ref id="bib134">
<mixed-citation publication-type="journal">Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. <article-title>Maternal immune activation alters fetal brain development through interleukin-6</article-title>. <source/>J Neurosci
<year>2007</year>; <volume>27</volume>: <fpage>10695</fpage>–10702.<pub-id pub-id-type="pmid">17913903</pub-id></mixed-citation>
</ref>
<ref id="bib135">
<mixed-citation publication-type="journal">Huang M, Pang X, Karalis K, Theoharides TC. <article-title>Stress-induced interleukin-6 release in mice is mast cell-dependent and more pronounced in Apolipoprotein E knockout mice</article-title>. <source/>Cardiovasc Res
<year>2003</year>; <volume>59</volume>: <fpage>241</fpage>–249.<pub-id pub-id-type="pmid">12829195</pub-id></mixed-citation>
</ref>
<ref id="bib136">
<mixed-citation publication-type="journal">Kandere-Grzybowska K, Letourneau R, Kempuraj D, Donelan J, Poplawski S, Boucher W et al. <article-title>IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells</article-title>. <source/>J Immunol
<year>2003</year>; <volume>171</volume>: <fpage>4830</fpage>–4836.<pub-id pub-id-type="pmid">14568962</pub-id></mixed-citation>
</ref>
<ref id="bib137">
<mixed-citation publication-type="journal">Theoharides TC, Boucher W, Spear K. <article-title>Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients</article-title>. <source/>Int Arch Allergy Immunol
<year>2002</year>; <volume>128</volume>: <fpage>344</fpage>–350.<pub-id pub-id-type="pmid">12218373</pub-id></mixed-citation>
</ref>
<ref id="bib138">
<mixed-citation publication-type="journal">Brockow K, Akin C, Huber M, Metcalfe DD. <article-title>IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis</article-title>. <source/>Clin Immunol
<year>2005</year>; <volume>115</volume>: <fpage>216</fpage>–223.<pub-id pub-id-type="pmid">15885646</pub-id></mixed-citation>
</ref>
<ref id="bib139">
<mixed-citation publication-type="journal">Mayado A, Teodosio C, Garcia-Montero AC, Matito A, Rodriguez-Caballero A, Morgado JM et al. <article-title>Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression</article-title>. <source/>Leukemia
<year>2015</year>; <volume>30</volume>: <fpage>124</fpage>–130.<pub-id pub-id-type="pmid">26153655</pub-id></mixed-citation>
</ref>
<ref id="bib140">
<mixed-citation publication-type="journal">Abdallah MW, Larsen N, Grove J, Norgaard-Pedersen B, Thorsen P, Mortensen EL et al. <article-title>Amniotic fluid chemokines and autism spectrum disorders: an exploratory study utilizing a Danish Historic Birth Cohort</article-title>. <source/>Brain Behav Immun
<year>2012</year>; <volume>26</volume>: <fpage>170</fpage>–176.<pub-id pub-id-type="pmid">21933705</pub-id></mixed-citation>
</ref>
<ref id="bib141">
<mixed-citation publication-type="journal">Zhang B, Weng Z, Sismanopoulos N, Asadi S, Therianou A, Alysandratos KD et al. <article-title>Mitochondria distinguish granule-stored from de novo synthesized tumor necrosis factor secretion in human mast cells</article-title>. <source/>Int Arch Allergy Immunol
<year>2012</year>; <volume>159</volume>: <fpage>23</fpage>–32.<pub-id pub-id-type="pmid">22555146</pub-id></mixed-citation>
</ref>
<ref id="bib142">
<mixed-citation publication-type="journal">Cohly HH, Panja A. <article-title>Immunological findings in autism</article-title>. <source/>Int Rev Neurobiol
<year>2005</year>; <volume>71</volume>: <fpage>317</fpage>–341.<pub-id pub-id-type="pmid">16512356</pub-id></mixed-citation>
</ref>
<ref id="bib143">
<mixed-citation publication-type="journal">Gomez G, Ramirez CD, Rivera J, Patel M, Norozian F, Wright HV et al. <article-title>TGF-beta1 inhibits mast cell FcåRI expression</article-title>. <source/>J Immunol
<year>2005</year>; <volume>174</volume>: <fpage>5987</fpage>–5993.<pub-id pub-id-type="pmid">15879091</pub-id></mixed-citation>
</ref>
<ref id="bib144">
<mixed-citation publication-type="journal">Kashyap M, Bailey DP, Gomez G, Rivera J, Huff TF, Ryan JJ. <article-title>TGF-beta1 inhibits late-stage mast cell maturation</article-title>. <source/>Exp Hematol
<year>2005</year>; <volume>33</volume>: <fpage>1281</fpage>–1291.<pub-id pub-id-type="pmid">16263412</pub-id></mixed-citation>
</ref>
<ref id="bib145">
<mixed-citation publication-type="journal">Jyonouchi H, Sun S, Le H. <article-title>Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression</article-title>. <source/>J Neuroimmunol
<year>2001</year>; <volume>120</volume>: <fpage>170</fpage>–179.<pub-id pub-id-type="pmid">11694332</pub-id></mixed-citation>
</ref>
<ref id="bib146">
<mixed-citation publication-type="journal">Naik US, Gangadharan C, Abbagani K, Nagalla B, Dasari N, Manna SK. <article-title>A study of nuclear transcription factor-kappa B in childhood autism</article-title>. <source/>PLoS One
<year>2011</year>; <volume>6</volume>: <fpage>e19488</fpage>.<pub-id pub-id-type="pmid">21573053</pub-id></mixed-citation>
</ref>
<ref id="bib147">
<mixed-citation publication-type="journal">Young AM, Campbell E, Lynch S, Suckling J, Powis SJ. <article-title>Aberrant NF-kappaB expression in autism spectrum condition: a mechanism for neuroinflammation</article-title>. <source/>Front Psychiatry
<year>2011</year>; <volume>2</volume>: <fpage>27</fpage>.<pub-id pub-id-type="pmid">21629840</pub-id></mixed-citation>
</ref>
<ref id="bib148">
<mixed-citation publication-type="journal">Ziats MN, Rennert OM. <article-title>Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways</article-title>. <source/>PLoS One
<year>2011</year>; <volume>6</volume>: <fpage>e24691</fpage>.<pub-id pub-id-type="pmid">21935439</pub-id></mixed-citation>
</ref>
<ref id="bib149">
<mixed-citation publication-type="journal">Nelissen S, Lemmens E, Geurts N, Kramer P, Maurer M, Hendriks J et al. <article-title>The role of mast cells in neuroinflammation</article-title>. <source/>Acta Neuropathol
<year>2013</year>; <volume>125</volume>: <fpage>637</fpage>–650.<pub-id pub-id-type="pmid">23404369</pub-id></mixed-citation>
</ref>
<ref id="bib150">
<mixed-citation publication-type="journal">Shemer A, Erny D, Jung S, Prinz M. <article-title>Microglia plasticity during health and disease: an immunological perspective</article-title>. <source/>Trends Immunol
<year>2015</year>; <volume>36</volume>: <fpage>614</fpage>–624.<pub-id pub-id-type="pmid">26431939</pub-id></mixed-citation>
</ref>
<ref id="bib151">
<mixed-citation publication-type="journal">Paolicelli RC, Bolasco G, Pagani F, Maggi L, Scianni M, Panzanelli P et al. <article-title>Synaptic pruning by microglia is necessary for normal brain development</article-title>. <source/>Science
<year>2011</year>; <volume>333</volume>: <fpage>1456</fpage>–1458.<pub-id pub-id-type="pmid">21778362</pub-id></mixed-citation>
</ref>
<ref id="bib152">
<mixed-citation publication-type="journal">Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R et al. <article-title>Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner</article-title>. <source/>Neuron
<year>2012</year>; <volume>74</volume>: <fpage>691</fpage>–705.<pub-id pub-id-type="pmid">22632727</pub-id></mixed-citation>
</ref>
<ref id="bib153">
<mixed-citation publication-type="journal">Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. <article-title>Neuroglial activation and neuroinflammation in the brain of patients with autism</article-title>. <source/>Ann Neurol
<year>2005</year>; <volume>57</volume>: <fpage>67</fpage>–81.<pub-id pub-id-type="pmid">15546155</pub-id></mixed-citation>
</ref>
<ref id="bib154">
<mixed-citation publication-type="journal">Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J et al. <article-title>Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism</article-title>. <source/>Biol Psychiatry
<year>2010</year>; <volume>68</volume>: <fpage>368</fpage>–376.<pub-id pub-id-type="pmid">20674603</pub-id></mixed-citation>
</ref>
<ref id="bib155">
<mixed-citation publication-type="journal">Morgan JT, Barger N, Amaral DG, Schumann CM. <article-title>Stereological study of amygdala glial populations in adolescents and adults with autism spectrum disorder</article-title>. <source/>PLoS One
<year>2014</year>; <volume>9</volume>: <fpage>e110356</fpage>.<pub-id pub-id-type="pmid">25330013</pub-id></mixed-citation>
</ref>
<ref id="bib156">
<mixed-citation publication-type="journal">Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J et al. <article-title>Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism</article-title>. <source/>Nat Commun
<year>2014</year>; <volume>5</volume>: <fpage>5748</fpage>.<pub-id pub-id-type="pmid">25494366</pub-id></mixed-citation>
</ref>
<ref id="bib157">
<mixed-citation publication-type="journal">Takano T. <article-title>Role of microglia in autism: recent advances</article-title>. <source/>Dev Neurosci
<year>2015</year>; <volume>37</volume>: <fpage>195</fpage>–202.<pub-id pub-id-type="pmid">25998072</pub-id></mixed-citation>
</ref>
<ref id="bib158">
<mixed-citation publication-type="journal">Koyama R, Ikegaya Y. <article-title>Microglia in the pathogenesis of autism spectrum disorders</article-title>. <source/>Neurosci Res
<year>2015</year>; <volume>100</volume>: <fpage>1</fpage>–5.<pub-id pub-id-type="pmid">26116891</pub-id></mixed-citation>
</ref>
<ref id="bib159">
<mixed-citation publication-type="journal">Wang W, Ji P, Riopelle RJ, Dow KE. <article-title>Functional expression of corticotropin-releasing hormone (CRH) receptor 1 in cultured rat microglia</article-title>. <source/>J Neurochem
<year>2002</year>; <volume>80</volume>: <fpage>287</fpage>–294.<pub-id pub-id-type="pmid">11902119</pub-id></mixed-citation>
</ref>
<ref id="bib160">
<mixed-citation publication-type="journal">Martin S, Vincent JP, Mazella J. <article-title>Involvement of the neurotensin receptor-3 in the neurotensin-induced migration of human microglia</article-title>. <source/>J Neurosci
<year>2003</year>; <volume>23</volume>: <fpage>1198</fpage>–1205.<pub-id pub-id-type="pmid">12598608</pub-id></mixed-citation>
</ref>
<ref id="bib161">
<mixed-citation publication-type="journal">Nykjaer A, Willnow TE. <article-title>Sortilin: a receptor to regulate neuronal viability and function</article-title>. <source/>Trends Neurosci
<year>2012</year>; <volume>35</volume>: <fpage>261</fpage>–270.<pub-id pub-id-type="pmid">22341525</pub-id></mixed-citation>
</ref>
<ref id="bib162">
<mixed-citation publication-type="journal">Buttenschon HN, Demontis D, Kaas M, Elfving B, Molgaard S, Gustafsen C et al. <article-title>Increased serum levels of sortilin are associated with depression and correlated with BDNF and VEGF</article-title>. <source/>Transl Psychiatry
<year>2015</year>; <volume>5</volume>: <fpage>e677</fpage>.<pub-id pub-id-type="pmid">26556286</pub-id></mixed-citation>
</ref>
<ref id="bib163">
<mixed-citation publication-type="journal">Ghanizadeh A. <article-title>Targeting neurotensin as a potential novel approach for the treatment of autism</article-title>. <source/>J Neuroinflammation
<year>2010</year>; <volume>7</volume>: <fpage>58</fpage>.<pub-id pub-id-type="pmid">20920308</pub-id></mixed-citation>
</ref>
<ref id="bib164">
<mixed-citation publication-type="book">Patel AB, Tsilioni I, Theoharides TC. <article-title>Neurotensin and corticotropin-releasing hormone synergistically activate human microglia through mammalian target ofrapamycin complex 1 (mTORC1), poster # A300</article-title>American Societies for Experimental Biology: Bethesda, MD, <year>2015</year>.</mixed-citation>
</ref>
<ref id="bib165">
<mixed-citation publication-type="journal">Lee dY. <article-title>Roles of mTOR signaling in brain development</article-title>. <source/>Exp Neurobiol
<year>2015</year>; <volume>24</volume>: <fpage>177</fpage>–185.<pub-id pub-id-type="pmid">26412966</pub-id></mixed-citation>
</ref>
<ref id="bib166">
<mixed-citation publication-type="journal">Lv JW, Cheng TL, Qiu ZL, Zhou WH. <article-title>Role of the PTEN signaling pathway in autism spectrum disorder</article-title>. <source/>Neurosci Bull
<year>2013</year>; <volume>29</volume>: <fpage>773</fpage>–778.<pub-id pub-id-type="pmid">24136242</pub-id></mixed-citation>
</ref>
<ref id="bib167">
<mixed-citation publication-type="journal">Tee AR, Sampson JR, Pal DK, Bateman JM. <article-title>The role of mTOR signalling in neurogenesis, insights from tuberous sclerosis complex</article-title>. <source/>Semin Cell Dev Biol
<year>2016</year>; <volume>52</volume>: <fpage>12</fpage>–20.<pub-id pub-id-type="pmid">26849906</pub-id></mixed-citation>
</ref>
<ref id="bib168">
<mixed-citation publication-type="journal">Kim MS, Kuehn HS, Metcalfe DD, Gilfillan AM. <article-title>Activation and function of the mTORC1 pathway in mast cells</article-title>. <source/>J Immunol
<year>2008</year>; <volume>180</volume>: <fpage>4586</fpage>–4595.<pub-id pub-id-type="pmid">18354181</pub-id></mixed-citation>
</ref>
<ref id="bib169">
<mixed-citation publication-type="journal">Dong H, Zhang W, Zeng X, Hu G, Zhang H, He S et al. <article-title>Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia</article-title>. <source/>Mol Neurobiol
<year>2014</year>; <volume>49</volume>: <fpage>1487</fpage>–1500.<pub-id pub-id-type="pmid">24752587</pub-id></mixed-citation>
</ref>
<ref id="bib170">
<mixed-citation publication-type="journal">Zhang S, Zeng X, Yang H, Hu G, He S. <article-title>Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling</article-title>. <source/>Cell Physiol Biochem
<year>2012</year>; <volume>29</volume>: <fpage>931</fpage>–940.<pub-id pub-id-type="pmid">22613992</pub-id></mixed-citation>
</ref>
<ref id="bib171">
<mixed-citation publication-type="journal">Skaper SD, Facci L, Giusti P. <article-title>Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review</article-title>. <source/>CNS Neurol Disord Drug Targets
<year>2014</year>; <volume>13</volume>: <fpage>1654</fpage>–1666.<pub-id pub-id-type="pmid">25470401</pub-id></mixed-citation>
</ref>
<ref id="bib172">
<mixed-citation publication-type="other">Dong H, Zhang X, Wang Y, Zhou X, Qian Y, Zhang S. <article-title>Suppression of brain mast cells degranulation inhibits microglial activation and central nervous system inflammation</article-title>. <source/>Mol Neurobiol
<year>2016</year> (in press).</mixed-citation>
</ref>
<ref id="bib173">
<mixed-citation publication-type="journal">Wong AY, Hsia Y, Chan EW, Murphy DG, Simonoff E, Buitelaar JK et al. <article-title>The variation of psychopharmacological prescription rates for people with autism spectrum disorder (ASD) in 30 Countries</article-title>. <source/>Autism Res
<year>2014</year>; <volume>7</volume>: <fpage>543</fpage>–554.<pub-id pub-id-type="pmid">24895332</pub-id></mixed-citation>
</ref>
<ref id="bib174">
<mixed-citation publication-type="journal">Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T et al. <article-title>Psychotropic medication use and polypharmacy in children with autism spectrum disorders</article-title>. <source/>Pediatrics
<year>2013</year>; <volume>132</volume>: <fpage>833</fpage>–840.<pub-id pub-id-type="pmid">24144704</pub-id></mixed-citation>
</ref>
<ref id="bib175">
<mixed-citation publication-type="journal">Schubart JR, Camacho F, Leslie D. <article-title>Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program</article-title>. <source/>Autism
<year>2014</year>; <volume>18</volume>: <fpage>631</fpage>–637.<pub-id pub-id-type="pmid">24165274</pub-id></mixed-citation>
</ref>
<ref id="bib176">
<mixed-citation publication-type="journal">Young NJ, Findling RL. <article-title>An update on pharmacotherapy for autism spectrum disorder in children and adolescents</article-title>. <source/>Curr Opin Psychiatry
<year>2015</year>; <volume>28</volume>: <fpage>91</fpage>–101.<pub-id pub-id-type="pmid">25602248</pub-id></mixed-citation>
</ref>
<ref id="bib177">
<mixed-citation publication-type="journal">Lake JK, Weiss JA, Dergal J, Lunsky Y. <article-title>Child, parent, and service predictors of psychotropic polypharmacy among adolescents and young adults with an autism spectrum disorder</article-title>. <source/>J Child Adolesc Psychopharmacol
<year>2014</year>; <volume>24</volume>: <fpage>486</fpage>–493.<pub-id pub-id-type="pmid">25329798</pub-id></mixed-citation>
</ref>
<ref id="bib178">
<mixed-citation publication-type="journal">Theoharides TC, Asadi S. <article-title>Unwanted interactions among psychotropic drugs and other treatments for autism spectrum disorders</article-title>. <source/>J Clin Psychopharmacol
<year>2012</year>; <volume>32</volume>: <fpage>437</fpage>–440.<pub-id pub-id-type="pmid">22722515</pub-id></mixed-citation>
</ref>
<ref id="bib179">
<mixed-citation publication-type="journal">Ecker C, Spooren W, Murphy D. <article-title>Developing new pharmacotherapies for autism</article-title>. <source/>J Intern Med
<year>2013</year>; <volume>274</volume>: <fpage>308</fpage>–320.<pub-id pub-id-type="pmid">23865950</pub-id></mixed-citation>
</ref>
<ref id="bib180">
<mixed-citation publication-type="journal">Chez MG, Guido-Estrada N. <article-title>Immune therapy in autism: historical experience and future directions with immunomodulatory therapy</article-title>. <source/>Neurotherapeutics
<year>2010</year>; <volume>7</volume>: <fpage>293</fpage>–301.<pub-id pub-id-type="pmid">20643382</pub-id></mixed-citation>
</ref>
<ref id="bib181">
<mixed-citation publication-type="other">Liew Z, Ritz B, Virk J, Olsen J. <article-title>Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: a Danish national birth cohort study</article-title>. <source/>Autism Res
<year>2015</year> (in press).</mixed-citation>
</ref>
<ref id="bib182">
<mixed-citation publication-type="journal">Curran LK, Newschaffer CJ, Lee LC, Crawford SO, Johnston MV, Zimmerman AW. <article-title>Behaviors associated with fever in children with autism spectrum disorders</article-title>. <source/>Pediatrics
<year>2007</year>; <volume>120</volume>: <fpage>e1386</fpage>–e1392.<pub-id pub-id-type="pmid">18055656</pub-id></mixed-citation>
</ref>
<ref id="bib183">
<mixed-citation publication-type="journal">Gupta S, Samra D, Agrawal S. <article-title>Adaptive and innate immune responses in autism: rationale for therapeutic use of intravenous immunoglobulin</article-title>. <source/>J Clin Immunol
<year>2010</year>; <volume>30</volume>(Suppl 1): <fpage>S90</fpage>–S96.<pub-id pub-id-type="pmid">20393790</pub-id></mixed-citation>
</ref>
<ref id="bib184">
<mixed-citation publication-type="other">Wong PH, White KM. <article-title>Impact of immunoglobulintherapy in pediatric disease: a review of immune mechanisms</article-title>. <source/>Clin Rev Allergy Immunol
<year>2015</year> (in press).</mixed-citation>
</ref>
<ref id="bib185">
<mixed-citation publication-type="journal">Plioplys AV. <article-title>Intravenous immunoglobulin treatment of children with autism</article-title>. <source/>J Child Neurol
<year>1998</year>; <volume>13</volume>: <fpage>79</fpage>–82.<pub-id pub-id-type="pmid">9512308</pub-id></mixed-citation>
</ref>
<ref id="bib186">
<mixed-citation publication-type="journal">Gupta S, Aggarwal S, Heads C. <article-title>Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics</article-title>. <source/>J Autism Dev Disord
<year>1996</year>; <volume>26</volume>: <fpage>439</fpage>–452.<pub-id pub-id-type="pmid">8863094</pub-id></mixed-citation>
</ref>
<ref id="bib187">
<mixed-citation publication-type="journal">Giudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. <article-title>Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism</article-title>. <source/>J Autism Dev Disord
<year>1999</year>; <volume>29</volume>: <fpage>157</fpage>–160.<pub-id pub-id-type="pmid">10382136</pub-id></mixed-citation>
</ref>
<ref id="bib188">
<mixed-citation publication-type="other">Melamed I, Gupta S, Bobbitt MS, Gilanders K, Hyland N, Moy JN. <article-title>Efficacy and Safety of Gammaplex® 5% in Children and AdolescentsAnchor with Primary Immunodeficiency Diseases</article-title>. IgNS Annual Conference Proceedings, <year>2015</year>; <fpage>228</fpage>–36.</mixed-citation>
</ref>
<ref id="bib189">
<mixed-citation publication-type="journal">Heuer LS, Rose M, Ashwood P, Van de Water J. <article-title>Decreased levels of total immunoglobulin in children with autism are not a result of B cell dysfunction</article-title>. <source/>J Neuroimmunol
<year>2012</year>; <volume>251</volume>: <fpage>94</fpage>–102.<pub-id pub-id-type="pmid">22854260</pub-id></mixed-citation>
</ref>
<ref id="bib190">
<mixed-citation publication-type="journal">Siniscalco D, Bradstreet JJ, Cirillo A, Antonucci N. <article-title>The <italic>in vitro</italic> GcMAF effects on endocannabinoid system transcriptionomics, receptor formation, and cell activity of autism-derived macrophages</article-title>. <source/>J Neuroinflammation
<year>2014</year>; <volume>11</volume>: <fpage>78</fpage>.<pub-id pub-id-type="pmid">24739187</pub-id></mixed-citation>
</ref>
<ref id="bib191">
<mixed-citation publication-type="journal">Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P et al. <article-title>Sulforaphane treatment of autism spectrum disorder (ASD)</article-title>. <source/>Proc Natl Acad Sci USA
<year>2014</year>; <volume>111</volume>: <fpage>15550</fpage>–15555.<pub-id pub-id-type="pmid">25313065</pub-id></mixed-citation>
</ref>
<ref id="bib192">
<mixed-citation publication-type="journal">King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L et al. <article-title>Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial</article-title>. <source/>JAMA Pediatr
<year>2013</year>; <volume>167</volume>: <fpage>1045</fpage>–1052.<pub-id pub-id-type="pmid">24061784</pub-id></mixed-citation>
</ref>
<ref id="bib193">
<mixed-citation publication-type="journal">Hardan AY, Fung LK, Libove RA, Obukhanych TV, Nair S, Herzenberg LA et al. <article-title>A randomized controlled pilot trial of oral N-acetylcysteine in children with autism</article-title>. <source/>Biol Psychiatry
<year>2012</year>; <volume>71</volume>: <fpage>956</fpage>–961.<pub-id pub-id-type="pmid">22342106</pub-id></mixed-citation>
</ref>
<ref id="bib194">
<mixed-citation publication-type="journal">Ghanizadeh A, Moghimi-Sarani E. <article-title>A randomized double blind placebo controlled clinical trial of N-Acetylcysteine added to risperidone for treating autistic disorders</article-title>. <source/>BMC Psychiatry
<year>2013</year>; <volume>13</volume>: <fpage>196</fpage>.<pub-id pub-id-type="pmid">23886027</pub-id></mixed-citation>
</ref>
<ref id="bib195">
<mixed-citation publication-type="journal">Deepmala, Slattery J, Kumar N, Delhey L, Berk M, Dean O et al. <article-title>Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review</article-title>. <source/>Neurosci Biobehav Rev
<year>2015</year>; <volume>55</volume>: <fpage>294</fpage>–321.<pub-id pub-id-type="pmid">25957927</pub-id></mixed-citation>
</ref>
<ref id="bib196">
<mixed-citation publication-type="journal">Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. <article-title>N-acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety</article-title>. <source/>Clin Neuropharmacol
<year>2015</year>; <volume>38</volume>: <fpage>11</fpage>–17.<pub-id pub-id-type="pmid">25580916</pub-id></mixed-citation>
</ref>
<ref id="bib197">
<mixed-citation publication-type="journal">Taliou A, Zintzaras E, Lykouras L, Francis K. <article-title>An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders</article-title>. <source/>Clin Ther
<year>2013</year>; <volume>35</volume>: <fpage>592</fpage>–602.<pub-id pub-id-type="pmid">23688534</pub-id></mixed-citation>
</ref>
<ref id="bib198">
<mixed-citation publication-type="journal">Theoharides TC, Asadi S, Panagiotidou S. <article-title>A case series of a luteolin formulation (Neuroprotek®) in children with autism spectrum disorders</article-title>. <source/>Intl J Immunopathol Pharmacol
<year>2012</year>; <volume>25</volume>: <fpage>317</fpage>–323.</mixed-citation>
</ref>
<ref id="bib199">
<mixed-citation publication-type="journal">Theoharides TC, Stewart JM, Hatziagelaki E, Kolaitis G. <article-title>Brain "fog," inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin</article-title>. <source/>Front Neurosci
<year>2015</year>; <volume>9</volume>: <fpage>225</fpage>.<pub-id pub-id-type="pmid">26190965</pub-id></mixed-citation>
</ref>
<ref id="bib200">
<mixed-citation publication-type="journal">Middleton EJ, Kandaswami C, Theoharides TC. <article-title>The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer</article-title>. <source/>Pharmacol Rev
<year>2000</year>; <volume>52</volume>: <fpage>673</fpage>–751.<pub-id pub-id-type="pmid">11121513</pub-id></mixed-citation>
</ref>
<ref id="bib201">
<mixed-citation publication-type="journal">Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y et al. <article-title>A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone</article-title>. <source/>Proc Natl Acad Sci USA
<year>2010</year>; <volume>107</volume>: <fpage>2687</fpage>–2692.<pub-id pub-id-type="pmid">20133810</pub-id></mixed-citation>
</ref>
<ref id="bib202">
<mixed-citation publication-type="journal">Scattoni ML, Martire A, Cartocci G, Ferrante A, Ricceri L. <article-title>Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+ tf/J strain, a mouse model of autism</article-title>. <source/>Behav Brain Res
<year>2013</year>; <volume>251</volume>: <fpage>35</fpage>–40.<pub-id pub-id-type="pmid">23270976</pub-id></mixed-citation>
</ref>
<ref id="bib203">
<mixed-citation publication-type="journal">Johnson RA, Lam M, Punzo AM, Li H, Lin BR, Ye K et al. <article-title>7,8-dihydroxyflavone exhibits therapeutic efficacy in a mouse model of Rett syndrome</article-title>. <source/>J Appl Physiol
<year>2012</year>; <volume>112</volume>: <fpage>704</fpage>–710.<pub-id pub-id-type="pmid">22194327</pub-id></mixed-citation>
</ref>
<ref id="bib204">
<mixed-citation publication-type="journal">Theoharides T, Athanassiou M, Panagiotidou S, Doyle R. <article-title>Dysregulated brain immunity and neurotrophin signaling in Rett syndrome and autism spectrum disorders</article-title>. <source/>J Neuroimmunol
<year>2015</year>; <volume>279</volume>: <fpage>33</fpage>–38.<pub-id pub-id-type="pmid">25669997</pub-id></mixed-citation>
</ref>
<ref id="bib205">
<mixed-citation publication-type="journal">Kimata M, Shichijo M, Miura T, Serizawa I, Inagaki N, Nagai H. <article-title>Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells</article-title>. <source/>Clin Exp Allergy
<year>2000</year>; <volume>30</volume>: <fpage>501</fpage>–508.<pub-id pub-id-type="pmid">10718847</pub-id></mixed-citation>
</ref>
<ref id="bib206">
<mixed-citation publication-type="journal">Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N et al. <article-title>Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells</article-title>. <source/>Br J Pharmacol
<year>2005</year>; <volume>145</volume>: <fpage>934</fpage>–944.<pub-id pub-id-type="pmid">15912140</pub-id></mixed-citation>
</ref>
<ref id="bib207">
<mixed-citation publication-type="journal">Weng Z, Patel A, Panagiotidou S, Theoharidess TC. <article-title>The novel flavone tetramethoxyluteolin is a potent inhibitor of human mast cells</article-title>. <source/>J Allergy Clin Immunol
<year>2014</year>; <volume>14</volume>: <fpage>1044</fpage>–1052.</mixed-citation>
</ref>
<ref id="bib208">
<mixed-citation publication-type="journal">Dirscherl K, Karlstetter M, Ebert S, Kraus D, Hlawatsch J, Walczak Y et al. <article-title>Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype</article-title>. <source/>J Neuroinflammation
<year>2010</year>; <volume>7</volume>: <fpage>3</fpage>.<pub-id pub-id-type="pmid">20074346</pub-id></mixed-citation>
</ref>
<ref id="bib209">
<mixed-citation publication-type="journal">Jang S, Kelley KW, Johnson RW. <article-title>Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1</article-title>. <source/>Proc Natl Acad Sci USA
<year>2008</year>; <volume>105</volume>: <fpage>7534</fpage>–7539.<pub-id pub-id-type="pmid">18490655</pub-id></mixed-citation>
</ref>
<ref id="bib210">
<mixed-citation publication-type="journal">Chen HQ, Jin ZY, Wang XJ, Xu XM, Deng L, Zhao JW. <article-title>Luteolin protects dopaminergic neurons from inflammation-induced injury through inhibition of microglial activation</article-title>. <source/>Neurosci Lett
<year>2008</year>; <volume>448</volume>: <fpage>175</fpage>–179.<pub-id pub-id-type="pmid">18952146</pub-id></mixed-citation>
</ref>
<ref id="bib211">
<mixed-citation publication-type="journal">Parker-Athill E, Luo D, Bailey A, Giunta B, Tian J, Shytle RD et al. <article-title>Flavonoids, a prenatal prophylaxis via targeting JAK2/STAT3 signaling to oppose IL-6/MIA associated autism</article-title>. <source/>J Neuroimmunol
<year>2009</year>; <volume>217</volume>: <fpage>20</fpage>–27.<pub-id pub-id-type="pmid">19766327</pub-id></mixed-citation>
</ref>
<ref id="bib212">
<mixed-citation publication-type="journal">Harwood M, nielewska-Nikiel B, Borzelleca JF, Flamm GW, Williams GM, Lines TC. <article-title>A critical review of the data related to the safety of quercetin and lack of evidence of <italic>in vivo</italic> toxicity, including lack of genotoxic/carcinogenic properties</article-title>. <source/>Food Chem Toxicol
<year>2007</year>; <volume>45</volume>: <fpage>2179</fpage>–2205.<pub-id pub-id-type="pmid">17698276</pub-id></mixed-citation>
</ref>
<ref id="bib213">
<mixed-citation publication-type="journal">Theoharides TC, Conti P, Economu M. <article-title>Brain inflammation, neuropsychiatric disorders, and immunoendocrine effects of luteolin</article-title>. <source/>J Clin Psychopharmacol
<year>2014</year>; <volume>34</volume>: <fpage>187</fpage>–189.<pub-id pub-id-type="pmid">24525647</pub-id></mixed-citation>
</ref>
<ref id="bib214">
<mixed-citation publication-type="journal">Jones QR, Warford J, Rupasinghe HP, Robertson GS. <article-title>Target-based selection of flavonoids for neurodegenerative disorders</article-title>. <source/>Trends Pharmacol Sci
<year>2012</year>; <volume>33</volume>: <fpage>602</fpage>–610.<pub-id pub-id-type="pmid">22980637</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1">
<label>Figure 1</label>
<caption>
<p>Schematic representation of the interactions among mast cells–microglia–neurons and the blood–brain barrier. Curved arrows, along with mediators associated with them, indicate action from one type of cell to another. The inhibitory action of luteolin (in box) is indicated by the inhibitory symbols (T). CRH, corticotropin-releasing hormone; IL, interleukin; NT, neurotensin; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.</p>
</caption>
<graphic xlink:href="tp201677f1" xmlns:xlink="http://www.w3.org/1999/xlink"></graphic>
</fig>
<table-wrap id="tbl1">
<label>Table 1</label>
<caption>
<title>ASD comorbidities or subgroups</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
</colgroup>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">ADD</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">ADHD</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Atopic diseases</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Food intolerance</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Gastrointestinal symptoms</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Mitochondrial dysfunction</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">PANDAS</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"><italic>PTEN</italic> mutations</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">Seizures</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t1-fn1">
<p>Abbreviations: ADD, attention deficit disorder; ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; PANDAS, pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections; PTEN, phosphatase and tensin homolog.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tbl2">
<label>Table 2</label>
<caption>
<title>Perinatal conditions increasing the risk of ASD</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
</colgroup>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">
<italic>Strong evidence</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Allergies</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Asthma</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Brain autoantibodies</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Brain hemorrhage</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Infection</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Low birth weight</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Obesity</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Preeclampsia</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Prematurity</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Psoriasis</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Stress</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> </td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">
<italic>Moderate evidence</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Cesarean section with general anesthesia</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Environmental toxin exposure</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Oxytocin, prolonged use for labor induction</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Psychotropic medication use</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Sexual abuse</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t2-fn1">
<p>Abbreviation: ASD, autism spectrum disorder.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tbl3">
<label>Table 3</label>
<caption>
<title>Evidence for inflammation of the brain</title>
</caption>
<table border="1" frame="hsides" rules="groups">
<colgroup>
<col align="left"/>
</colgroup>
<tbody valign="top">
<tr>
<td align="left" charoff="50" valign="top">
<italic>Brain</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Microglia activation</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Microglia proliferation</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-1β ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-6 ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-17 ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> TNF ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> </td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">
<italic>Blood</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Auto-brain antibodies ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-1β ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-6 ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-17 ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> TNF ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> NF-κB ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> </td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">
<italic>Neonatal blood</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> MCP-1 ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> </td>
</tr>
<tr>
<td align="left" charoff="50" valign="top">
<italic>Midgestational blood</italic>
</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> Auto-brain antibodies ↑</td>
</tr>
<tr>
<td align="left" charoff="50" valign="top"> IL-4, IL-5, IFN-γ ↑</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="t3-fn1">
<p>Abbreviations: IL, interleukin; TNF, tumor necrosis factor.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>